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Abstract 
Few studies have comprehensively explored the benefit of fetal tissue 
implantation in Parkinson’s disease (PD) patients. This type of investigation is necessary 
to better understand how and why some participants in a double-blind investigation of 
fetal tissue implantation for PD improved following the surgical procedure while others 
did not (Freed et al., 2001). Data for the present study were collected during a quality of 
life (QoL) study conducted by McRae et al. (2004) that sampled PD patients who 
participated in Freed et al.’s (2001) double-blind investigation of fetal tissue 
implantation. Several aspects of QoL were examined in McRae et al.’s (2004) study, 
including perceived social support and self-efficacy.  
The literature on chronic disease management has consistently demonstrated the 
important role self-efficacy and social support have on the overall functioning of those 
living with chronic disease, specifically PD (Chenoweth, Gallager, Sheriff, Donoghue, & 
Stein-Parbury, 2008; Montgomery, Lieberman, Sing, & Fries, 1994; Schreurs, De Ridder, 
& Bensing, 2000; Simpson, Haines, Lekwuwa, Wardle, & Crawford, 2006). Additionally, 
literature on the placebo effect has suggested that higher levels of self-efficacy and 
perceived social support can enhance and sustain the placebo effect (Crow et al., 1999; 
Howard, 2008; Kaptchuk et al., 2008; Miller et al., 2009). The present study examined 
the predictive ability of perceived social support and self-efficacy in regard to physical 
functioning and perceived treatment in a sample of PD patients who received fetal tissue 
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implantation. The study uniquely contributed to the literature because it was the first to 
examine the role of self-efficacy and the interaction between self-efficacy and social 
support on physical functioning and perceived treatment within this participant sample.  
Results indicated that self-efficacy was a significant predictor of physical 
functioning at 12-months post-fetal tissue implantation while social support was not 
found to be a significant predictor. Self-efficacy and social support were not significant 
predictors of patients’ physical functioning 24-months post-fetal tissue implantation or of 
patients’ perceived treatment group 12-months after the initial surgery. Future research 
studies might consider examining the longitudinal role of social support and self-efficacy 
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Chapter One: Introduction 
 
Description of Parkinson’s disease 
 Parkinson’s disease (PD) is a chronic and progressive neurological disease that 
produces numerous motor and non-motor symptoms in those living with the disease 
(Jankovic, 2007). This disease is the most common neurodegenerative disorder in the 
aging population (Prakash & Tan, 2010). Specifically, PD is prevalent in 1% of adults 60 
years and older in industrialized countries, affecting more than six million people 
worldwide and more than one million individuals in the United States (Post et al., 2007; 
Prakash & Tan, 2010; Menza et al., 2009). The pathology of PD is explained by a loss of 
dopamine neurons in the substantia nigra, a part of the basal ganglia region of the brain 
(Jankovic, 2007). Symptoms differ in presentation and severity from patient to patient 
and similarly have a variable impact on the lives of those with PD.  
Onset, Progression, and Symptoms of PD 
The onset of PD typically occurs between the ages of 55 and 75 (Jankovic, 2007). 
Clinical studies have tracked the course of the disease and have determined that its 
progression is variable rather than linear. Postural instability and gait difficulty are two 
symptoms that predict a more rapid deterioration in the earlier stages of PD. These two 
symptoms are the strongest prognostic factors of impairment and disability (Jankovic, 
2007; Post et al., 2007). 
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The four cardinal motor symptoms of PD are tremor at rest, rigidity, akinesia, and 
postural instability. Flexed posture and freezing, or motor blocks, are two other classic 
symptoms of PD (Jankovic, 2007). The most common non-motor features of PD include 
autonomic dysfunction, cognitive or neurobehavioral disorders, sensory abnormalities, 
and sleep abnormalities. Cognitive decline and dementia are the most common cognitive 
dysfunctions that occur in the PD population. Neuropsychiatric disorders, such as 
depression and anxiety, often are present in the PD population, particularly in those who 
suffer from dementia as well (Jankovic, 2007). In fact, depression has been estimated to 
be prevalent in around 50% of the PD population (Ravina et al., 2007). Depression in 
patients with PD is often related to other clinical domains such as quality of life, 
progression of physical symptoms, and ability to care for oneself (Schrag, 2006). 
Treatment of Parkinson’s disease 
 While there is no cure for PD, the disease can be treated with various drug and 
surgical interventions, which assist in treating the symptoms and managing the disease. 
These interventions help to decrease the interference the disease has on PD patients’ 
lives. These interventions can contribute to maintaining the quality of life and level of 
functionality desired by patients and their families.  
 The standard drug treatment for PD is with Levodopa or L-dopa (Krack et al., 
2003). L-dopa is a dopamine agonist that operates as a substitute for the loss of dopamine 
in the basal ganglia. Cotzias et al. (1967) first discovered this drug treatment in 1967 and 
it has since remained the primary drug intervention to decrease the severity of the motor 
symptoms in PD. While this treatment benefits PD patients, responsiveness to this drug 
often decreases within five to ten years (Clarkson, 2001). Additional disadvantages of the 
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L-dopa treatment stem from the “on” and “off” periods when patients experience 
fluctuations in the therapeutic benefit. Specifically, those with PD experience 
improvements in mobility during the “on” periods but then also experience the return of 
active motor symptoms during the “off” periods (Limousin et al., 1998). Current research 
is focused on improving the mechanism of the L-dopa treatment in order to prolong its 
therapeutic benefit (Goole & Amighi, 2009). To sum, this drug treatment has advantages 
to PD patients through the drug’s ability to decrease motor symptoms; however, the 
complications and disadvantages involved with L-dopa use, particularly the decrease in 
effectiveness over time, often lead patients to explore other treatments for the PD.  
Surgical interventions are one type of alternative treatment that can be pursued by 
PD patients. Most surgical interventions for PD attempt to increase dopamine production 
in the brain through in vivo techniques (Clarkson, 2001). Gene therapy, deep brain 
stimulation, and neuronal implantation are examples of surgical interventions for PD.  
 Gene therapy is a surgical intervention that attempts to re-establish normal brain 
activity by introducing a new gene into the area of the brain that is diseased (Kaplitt et 
al., 2007). In PD patients, gene therapies have introduced new genes into the basal 
ganglia region of the brain with hope of ultimately modifying neurotransmitter levels 
(Fiandaca, Forsayeth, & Bankiewicz, 2008). To date, three studies with small sample 
sizes have implemented gene therapy and have demonstrated the practicality and safety 
of this procedure. Gene therapy was originally developed as a research tool, but currently 
researchers are exploring ways to develop it as a clinical treatment because of its 
potential to alter the course of chronic diseases, such as PD. Long-term follow-up studies 
have yet to demonstrate the efficacy and long-term effects of gene therapy and thus this 
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surgical intervention has not yet been widely used with PD patients (Fiandaca et al., 
2008). 
 A second type of surgical intervention that has been developed in attempts to treat 
the motor symptoms of PD is deep brain stimulation (DBS); (Limousin et al, 1998). DBS 
is a procedure that implants electrodes into the subthalamic nucleus of the brain, which 
are then stimulated with high frequency waves. This stimulation functions to decrease the 
debilitating motor symptoms observed in PD patients (Limousin et al, 1998). Researchers 
have conducted numerous long-term follow-ups since Limousin et al. first developed 
DBS in 1998, and the results are encouraging. PD patients have demonstrated 
improvements in a variety of motor symptoms that have been sustained for more than 
five years (Krack et al., 2003). Due to these encouraging results of long-term follow-up 
studies, DBS is considered by many to be the surgical intervention of choice for PD 
patients (Krack et al., 2003). 
 The third type of surgical intervention is neural implantation. Specifically, fetal 
tissue implantation has been the primary form of neural implantation used in the 
treatment of PD. Fetal tissue implantation is a surgical intervention that introduces fetal 
tissue into the brain to regenerate neurons lost due to neurologic disease. The best results 
of fetal tissue implantation in PD patients have come from studies where dopaminergic 
neurons have been derived from human fetal ventral mesencephalon (Clarkson, 2001). 
Since Lindvall et al. first conducted fetal tissue implantations with PD patients in 1989, 
patients have demonstrated improvements in motor symptoms and reduced necessary 
doses of L-dopa (Clarkson, 2001). As reviewed by Clarkson and Freed (1999), a series of 
open label trials of fetal tissue implantation were conducted with small sample sizes 
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throughout the 1990s. These trials demonstrated improvements in motor functions and 
decreases in the necessary dosages of L-dopa (Clarkson & Freed, 1999). In a later review 
of these clinical trials of fetal tissue implantation in PD patients, Clarkson (2001) 
determined that about two-thirds of PD patients exhibit moderate improvements in motor 
function following this surgical intervention.  
Freed et al. (2001) assessed the efficacy of fetal tissue implantation through the 
first double-blind trial. One half of the PD patients received fetal tissue implantation and 
the other received a sham surgery. The study examined changes in PD symptoms in the 
implant surgery group compared to the sham surgery group by controlling for placebo 
effect of the surgery (Freed et al., 2001). Freed et al. found that 65% of those in the 
implant group demonstrated increases in dopamine activity while those in the sham 
surgery group did not demonstrate these same improvements. Patients who were 60-
years-old or younger exhibited a significant decrease in motor symptoms; however, older 
patients showed little to no improvement in motor symptoms (Freed et al., 2001). By the 
12-month follow-up, 15% of those in the implant group developed dystonia or 
dyskinesia. While the study demonstrated variable efficacy of fetal tissue implantation on 
PD symptoms, these conclusions were important for future developments in surgical 
interventions of PD (Freed et al., 2001). This examination of neural implantation reported 
by Freed et al. (2001) served as the foundational study upon which the present 
investigation was based.  
 To summarize the treatments available for PD, gene therapy and DBS have 
demonstrated potential for the treatment of PD today and in the future. These two 
procedures were developed in response to variable successes demonstrated by past 
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attempts to treat PD through surgical interventions. The history of surgical interventions 
for PD includes lesioning procedures, such as thalamotomies and pallidotomies, as well 
as implantation of adrenal tissue into the brain. Gene therapy and DBS were still in their 
infancy when participants in the present study received fetal tissue implantation in the 
second half of the 1990s (Freed et al., 2001). While fetal tissue implantation was 
developed more than 20 years ago, many have argued that there are areas involved in 
neural implantation that deserve further development (Lindvall, Kokaia, & Martinez-
Serrano, 2004). Specifically, the mechanisms through which this intervention is most 
effective along with an examination of which types of patients have demonstrated the 
most benefit from neural implantation are topics that should be explored (Lindvall et al., 
2004). These explorations will assist in the development of future neuronal implantation 
interventions and will inform the overall treatment process of PD. Moreover, little is 
known about the effect or predictive ability of quality of life variables on the treatment 
outcome of procedures such as neural implantation in the PD population (McRae et al., 
2004). Therefore, the focus of the present study will explore the role of quality of life 
variables on the physical functioning benefits observed in some PD patients following 
fetal tissue implantations conducted during the parent study. These quality of life 
variables and changes in physical functioning will also be explored in the context of the 
placebo effect given the double-blind methodological design of the parent study by Freed 
et al. (2001). 
Quality of Life 
 Quality of life (QoL) is a comprehensive term used to describe a variety of 
domains of an individual’s life. Despite the range of drug and surgical treatments, QoL in 
 
7 
those living with PD is affected in a variety of arenas and dimensions due to fluctuating 
motor and non-motor symptoms, progression, and unpredictability of the disease 
(Reuther et al., 2007). Side effects of medications also contribute to the QoL for those 
with PD. Additionally, depression and anxiety commonly develop in those with PD and 
ultimately have negative effects on QoL (Jankovic, 2007). Some patients may find it 
harder to leave the house, feel embarrassed by the symptoms, and struggle with the 
inability to depend on being “on.” Whether considered independently or collectively, 
these changes in physical and emotional functioning can influence the social relationships 
and general social functioning of patients with PD. All of these domains, physical, 
emotional, and social functioning, have important implications on QoL. These three 
domains were the focus of examination in a QoL study conducted by McRae et al. (2004) 
which followed many of the PD patients who participated in the parent study (Freed et 
al., 2001). The QoL study was the source of data for the present study.  
Self-efficacy 
 One aspect of QoL that was not examined in the original QoL study is self-
efficacy. Research questions in the present study explored this variable and how it 
contributed to the beneficial treatment outcome observed in some PD patients following 
fetal tissue implantation. Self-efficacy has been examined by numerous studies in the 
health psychology literature, most of which have demonstrated the influential role self-
efficacy plays in a variety of health related outcomes (Lorig, Mazonson, & Holman, 
1993; Schwarzer & Fuchs, 1995). This construct has been explored in the context of 
adoption of health behaviors as well as in the management of chronic disease. Self-
efficacy was first found to benefit the outcome of self-management activities in patients 
 
8 
with arthritis and now has been extended to a range of chronic diseases (Lorig et al., 
1993; Lorig et al., 2001). Self-efficacy has been a focus in the literature because it is one 
of the few factors related to chronic disease management that is amenable to change. 
Therefore, interventions such as The Chronic Disease Self-Management Program of 
Stanford University’s School of Medicine have been developed to increase self-efficacy 
in the chronic disease population (Lorig et al., 2001). Stanford’s program has developed 
curriculums specific to patients with a range of chronic diseases such as HIV/AIDS, 
diabetes, chronic pain, and arthritis (Lorig et al., 2001). Results from these studies 
demonstrate multiple beneficial health outcomes as a result of increased self-management 
self-efficacy, such as decreased disability, fewer medical visits, and less fatigue, and they 
appear to be maintained over time (Lorig et al., 2001).  
Few studies have examined the role of self-efficacy in the management of PD. 
However, existing evidence suggests that there are beneficial effects of high levels of 
self-efficacy on management of PD (Chenoweth et al., 2008; Peteet, 2002, as cited in 
Chenoweth, et al., 2008; Montgomery et al., 1994). This evidence justifies the 
examination of self-efficacy in the PD population, particularly throughout the 
implementation of a medical intervention such as fetal tissue implantation. A measure of 
self-efficacy was adapted by Lorig et al.’s (1993) previous work and was used by McRae 
et al. (2004) in the QoL study to assess PD patients’ self-efficacy related to the 
management of their disease and attending circumstances at baseline and during each 






A second variable that was examined in the original QoL study and has been 
widely studied in the psychological and medical literature in a range of patient 
populations was social support. Along with self-efficacy, the research questions of the 
preset study explored how perceived social support is related to the beneficial treatment 
outcome observed in some PD patients following fetal tissue implantation. Social support 
has been found to have beneficial effects on the management of chronic disease, 
commitment to medical regimens, and response to physiological stress. In response to the 
positive health outcomes observed in other chronic disease populations, the role of social 
support has been examined in the PD population (Brod, Mendelsohn, & Roberts, 1998 as 
cited in Backer, 2000; Ehman, Beninger, & Gawel, 1990; Schreurs et al., 2000; Simpson 
et al., 2006). This research affirms that there are a variety of benefits that social support 
provides to the management of and coping with chronic diseases such as PD. In the 
original QoL study, McRae et al. (2004) assessed perceived social support with the Social 
Provisions Scale (Cutrona & Russell, 1987). 
 Despite the well-documented independent beneficial effects of social support and 
self-efficacy on health outcomes, few studies have examined the interrelationship of these 
two constructs on health outcomes in chronic disease patients. Those studies that have, 
found a positive relationship between self-management behaviors, social support, and 
self-efficacy (Kaşikçi & Alberto, 2007). Therefore, these variables appear to be 
interrelated and should be investigated collectively in chronic disease populations. The 
present study sought to further establish this relationship within the context of PD 




 In attempt to examine the efficacy of fetal tissue implantation, the parent study 
compared changes in PD symptoms between the implant surgery group and the sham or 
control surgery group (Freed et al., 2001). This design was used to control for the effects 
of perceived treatment or placebo responses on changes in PD symptoms following a 
surgical intervention. The placebo effect is a phenomenon that has been recognized and 
discussed for many years. Improvements in a variety of medical diseases have been 
associated with placebos, particularly following sham surgeries (Goetz et al., 2008; 
Birch, 2006).  
The placebo effect has been found to operate through a variety of mechanisms, 
and two that have been explored are self-efficacy and social support. In a meta-analysis 
of numerous articles, Crow et al. (1999) examined the role of expectancies in the placebo 
effect. In the context of Crow et al.’s (1999) review, expectancies refer to the patient’s 
expected outcomes following a medical intervention. Similarly, patient-related self-
efficacy expectancies exist, such as self-management self-efficacy or patients’ beliefs that 
they can perform particular skills to manage the effects of an intervention or of their 
disease (Crow et al., 1999). Crow et al. (1999) conceptualized the placebo effect within 
four main determinants (patient, provider, patient-provider interaction, and 
treatment/setting) and four primary mechanisms (expectancy, anxiety reduction, classical 
conditioning, and social support) that were thought to act on health outcomes (health 
status, self-report, and objective measures). Within the mechanism of expectancy, various 
forms of self-efficacy (process expectancy, positive and negative outcome expectancy, 
interaction self-efficacy, and self-management self-efficacy) have been related to the 
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placebo effect, how it operates, and how it produces responses (Crow et al., 1999). In 
theory, enhancements in self-efficacy will lead to increases in the placebo response, and 
within the health care field this increase in placebo response translates to improvements 
in health outcomes (Crow et al., 1999). This theory is supported by research that 
demonstrates enhancements in general health following increases in self-efficacy 
(Holman & Lorig, 1992; Schwarzer & Fuchs, 1995) and by literature that illustrates 
health benefits following from placebo responses to medical interventions (Birch, 2006). 
In their review, Crow et al. (1999) conclude that the literature indicates that increases in 
various forms of self-efficacy lead to enhancements in placebo responses. Similarly, 
social support has been found to be a mechanism through which the placebo response 
operates. Some studies have even demonstrated that the placebo effect is enhanced and 
sustained when supplemented with perceptions of social support (Kaptchuk et al., 2009). 
Therefore, these two QoL variables, self-efficacy and perceived social support, were 
examined as mechanisms of the placebo effect, based on patients’ perceived treatment, 
observed in PD patients following either an actual or a sham fetal tissue implantation 
surgery in the parent study.   
Statement of Purpose 
 While numerous studies have been conducted to explore the efficacy of surgical 
interventions on the symptoms of PD, few studies have comprehensively explored the 
benefit of fetal tissue implantation. In particular, researchers have not identified the 
characteristics that make patients good candidates for this treatment with the exception of 
age, as discussed in Freed et al.’s (2001) investigation. In other words, researchers have 
not explored the variables that likely contribute to positive outcomes following the 
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procedure. Also, few studies have investigated the mechanisms through which potential 
benefits of fetal tissue implantation are likely to operate (Lindvall et al., 2004). As 
previously mentioned, this type of investigation is necessary to better understand how 
and why some PD patients improved following fetal tissue implantation in the parent 
study while others did not (Freed et al., 2001). Likewise, this sort of study will inform 
future surgical interventions with PD patients and assist in selecting candidates who 
might benefit the most from these surgeries. Additionally, this information can assist in 
determining domains of patient life that may require preliminary intervention or 
improvement prior to undergoing an invasive surgical procedure such as fetal tissue 
implantation. For example, interventions designed to improve patients’ level of self-
management self-efficacy, such as Lorig’s (2001) Chronic Disease Self-Management 
Program, may be implemented prior to a surgical procedure in attempt to increase the 
potential benefit of surgery. 
The present study attempted to address this gap in the literature by exploring the 
relationship of self-efficacy and social support on physical functioning in PD patients 
following fetal tissue implantation and at several follow-up assessments. Moreover, this 
study explored the relationship between self-efficacy, social support, and perception of 
treatment within this sample of PD patients who either received an actual fetal tissue 
implantation surgery or a sham surgery prior to the actual fetal tissue implantation. This 
investigation made a unique contribution to the literature by describing the role of self-
efficacy and social support in physical functioning and perceived treatment observed in 
PD patients following fetal tissue implantation or sham surgery.  
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 The literature on chronic disease management has consistently demonstrated the 
important role self-efficacy and social support have on the lives and overall functioning 
of those living with chronic disease. This research has extended specifically to patients 
living with PD and has illustrated that higher levels of perceived social support and self-
management self-efficacy lead to more positive health outcomes within this population. 
Moreover, the literature has begun exploring the interrelationship between these two 
variables, self-efficacy and social support, within the chronic disease population 
(Chenoweth et al., 2008; Peteet, 2002 as cited in Chenoweth et al. 2008). While sparse, 
this growing research suggests that self-efficacy and perceived social support work 
collectively to benefit individuals managing chronic diseases (Kaşikçi & Alberto, 2007). 
The benefit of these variables would likely be of particular importance following medical 
interventions, such as surgery. Hence, the present study explored the relationship between 
these two constructs within the PD population following fetal tissue implantation.   
 Lastly, due to the unique design of the parent study, self-efficacy and social 
support were also explored as contributors to the placebo effect or as predictors of 
patients’ perceived treatment group (real or sham surgery). Literature on the placebo 
effect has suggested that higher levels of self-efficacy and perceived social support can 
enhance and sustain the placebo effect (Crow et al., 1999; Howard, 2008; Kaptchuk et al., 
2008; Miller et al., 2009). This enhancement can lead to greater improvements in health 
outcomes such as physical functioning. Therefore, the present study sought to describe 
how these variables operate collectively and explored the effect this relationship may 
have on the physical functioning of PD patients following fetal tissue implantation.  
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 Data for the present study were collected during the original QoL life study 
conducted by McRae et al. (2004). Thirty of the 40 patients who participated in Freed et 
al.’s (2001) parent study agreed to participate in the QoL study. Data on these QoL 
variables were collected at baseline, four-, eight-, 12-, 24-, and 36-month follow-up 
assessments. The present study examined the predictive ability of self-efficacy and 
perceived social support at baseline on physical functioning at 12- and 24-months post-
fetal tissue implantation and perceived treatment of the patients 12-months after the 
initial surgery. Because patients who originally received the sham surgery were given the 
opportunity to have the actual fetal tissue implantation once the blind was lifted 13-
months after the initial surgery, this study examined the patient data at 12- and 24-months 
after the actual fetal tissue implantation (or 24- and 36-months after the initial surgery for 
those in the sham surgery group).  
Research Questions 
1. Are self-efficacy and perceived social support at adjusted baseline correlated 
with physical functioning at 12- and 24-months post-fetal tissue implantation? 
2a. Do self-efficacy and perceived social support at adjusted baseline predict 
physical functioning of PD patients 12-months following fetal tissue implantation? Does 
the interaction term of social support x self-efficacy at adjusted baseline predict physical 
functioning of PD patients 12-months following fetal tissue implantation? 
2b. Do self-efficacy and perceived social support at adjusted baseline predict 
physical functioning 24-months following fetal tissue implantation? Does the interaction 
term of social support x self-efficacy at adjusted baseline predict physical functioning of 
PD patients 24-months following fetal tissue implantation? 
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3. Do self-efficacy and perceived social support at true baseline predict perceived 
treatment at 12-months after the initial surgery? 
Summary 
 Chapter One provided an introduction of PD and the parent study upon which the 
present investigation was based. Specifically, a definition of the disease and its onset, 
symptoms, progression, and treatments were described. The impact of PD was discussed 
in terms of QoL implications and a brief overview of the various domains that comprise 
QoL in this study was presented. A summary of the present study was provided and 
accompanied by a rationalization for further study within the PD population following 
fetal tissue implantation. In Chapter Two, a more comprehensive review of the literature 
on PD, drug treatments, surgical treatments (specifically fetal tissue implantation), self-
efficacy, perceived social support, and the placebo effect will be presented.   
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Chapter Two: Literature Review 
Introduction 
 Chapter Two provides a review of relevant literature on PD and related treatment 
approaches. This chapter will examine the placebo effect, its determinants and influences, 
and its role in medical interventions, particularly in relation to those with PD. Self-
efficacy will also be discussed in general as well as in the context of medical 
interventions and self-management of chronic disease. Next, social support will be 
explored as a general construct and then as a mechanism through which the placebo 
effect operates and ultimately effects health outcomes. Lastly, relationships between the 
domains of the placebo effect, self-efficacy, and social support will be explained.  
The literature reviewed in this chapter was obtained through Internet searches in 
the following medical and psychological databases: PsychINFO, PsychArticles, 
MEDLINE, HealthFinder, and Academic Search Premier. The search terms used were 
Parkinson’s disease, levodopa, gene therapy, stem cell implantation, fetal tissue 
implantation, lesions, placebo effect, self-efficacy, self-management, self-care, quality of 
life, and social support. Books were also obtained from local university libraries that 
discussed the placebo effect, self-efficacy, and social support. Lastly, the reference lists 
from identified sources were reviewed to locate additional works or authors that were 





Originally studied by and later named after James Parkinson, Parkinson’s disease 
(PD) is the most common neurodegenerative disease in the aging population (Prakash & 
Tan, 2010). PD is a progressive neurological disorder that affects a number of motor and 
non-motor features (Jankovic, 2007). These features differ in their severity and have a 
variable impact on the functioning of those who have been diagnosed with PD. The 
disease is diagnosed based on a set of clinical criteria and cannot be determined by a 
single test. In its early stages, PD symptoms can appear to be similar to those of other 
diseases, primarily essential tremor, multiple system atrophy with parkinsonism, and 
progressive supranuclear palsy (Prakash & Tan, 2010). The pathology of PD is 
characterized by a “loss of dopaminergic neurons in the substantic nigra pars compacta 
(SNc) and accumulation of α-synuclein (α-SYN) containing Lewy bodies and neuritis” 
(Cersosimo & Benarroch, 2012).  
 Onset and progression. The age of onset of PD is typically between 55 and 75 
years old (Jankovic, 2007). Many studies have attempted to track the progression of PD 
and have concluded that the progression of the disease is variable rather than linear. This 
research suggests that the deterioration is more rapid in patients with postural instability 
and gait difficulty in the earlier phases of PD (Jankovic, 2007). Post, Merkus, de Haan, 
and Speelman (2007) found that advanced age, postural instability, and gait difficulty are 
the strongest prognostic factors for impairment and disability. Other studies have also 
suggested that early signs of cognitive impairment and severity of motor symptoms at 
baseline are strong predictors of advanced motor impairment and disability (as cited in 
Post et al., 2007). 
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 Prevalence. PD affects more than six million people worldwide and more than 
one million individuals in the United States (Prakash & Tan, 2010; Menza et al., 2009). It 
is considered the most common neurodegenerative movement disorder worldwide and the 
second-most common in the U.S. (Prakash & Tan, 2010; Menza et al., 2009). The 
prevalence of PD in industrialized countries in adults 60 years and older is 1% (Post et 
al., 2007).  
Recent public health research has examined the effects of race and ethnicity on 
the diagnosis of PD. One such study by Dahodwala et al. (2009) concluded that African 
Americans had a relative risk of .43 and Latinos had a relative risk of .74 for being 
diagnosed with PD in comparison to their White counterparts. Dahodwala et al. (2009) 
did not report a relative risk for Asian Americans or other racial minority groups. 
However, another study by Willis, Evanoff, Lian, Criswell, and Racette (2010) examined 
racial differences in the incidence and prevalence of PD and concluded that Whites have 
a “substantially higher prevalence and incidence of PD” compared to African or Asian 
Americans. The analyses of Dahodwala et al.’s (2009) study adjusted for several other 
demographic variables including age, sex, income, and healthcare utilization and 
determined that racial differences observed in the diagnosis of PD were not explained by 
any of these variables (Dahodwala et al., 2009). Instead, Dahodwala et al. (2009) 
speculated that the observed racial differences may be accounted for by biological 
differences, education, or beliefs about aging and urged that future research continue to 
explore the “complex biological and social determinants of these disparities” in order to 
improve the healthcare of those with PD. 
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 Symptoms. There are four cardinal motor features of PD: tremor at rest, rigidity, 
akinesia or bradykinesia, and postural instability (Jankovic, 2007). Two other classic 
features of PD are flexed posture and freezing, otherwise referred to as motor blocks. 
Other secondary motor symptoms include hypomimia, dysarthria, dysphagia, and 
sialorrhoea (Jankovic, 2007). The non-motor features of PD include autonomic 
dysfunction, cognitive or neurobehavioral disorders, sensory abnormalities, and sleep 
abnormalities. Autonomic dysfunction in patients with PD can manifest as sweating, 
sphincter and erectile dysfunction, and orthostatic hypotension (Jankovic, 2007). Typical 
cognitive dysfunctions include some form of decline or dementia. Dementia in PD 
patients is often associated with neuropsychiatric disorders such as depression and 
anxiety (Jankovic, 2007). The prevalence of depression in the PD population has been 
estimated to be at 50% and is associated with many poor outcome variables, such as 
decline in quality of life, progression of physical symptoms, and inability to care for 
oneself (Ravina et al., 2007; Schrag, 2006). Olfactory dysfunction, depression, and rapid 
eye movement sleep behavior disorder are non-motor symptoms that are considered to be 
preclinical markers of PD. An assessment of these non-motor symptoms is thought to 
assist in identifying groups that are at risk for developing PD (Prakash & Tan, 2010).  
Treatment of Parkinson’s disease 
 Drug treatments. Levodopa (L-dopa) is the standard drug treatment for PD 
(Krack et al., 2003). L-dopa is a dopamine agonist or pro-drug that substitutes for the loss 
of dopamine in the basal ganglia, which is related to the presence of PD symptoms 
(Goole & Amighi, 2009). Once administered, L-dopa is converted to dopamine and 
stored in corresponding neurons. This drug was first discovered by Cotzias et al. (1967) 
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and was a dramatic breakthrough in the treatment of PD at that time. The most common 
drug treatment for PD combines L-dopa with the decarboxylase inhibitor, carbidopa 
(Clarkson, 2001). This medication combination reduces the breakdown of L-dopa in the 
intestines, ultimately increasing its bioavailability (Clarkson, 2001).  
However, this drug treatment has been shown to lead to long-term motor 
complications (Clarkson, 2001). Responsiveness to L-dopa has been shown to decrease 
over time, often within five to 10 years. This decrease in responsiveness is related to 
“progressive degeneration of nigral dopaminergic neurons” that results in a loss of 
dopamine buffering and ultimately, dyskinesia in patients (Clarkson, 2001; Goole & 
Amighi, 2009). Specifically, L-dopa exhibits fluctuations between “on” effects, when the 
medication produces improvements in mobility, and “off” effects, when the medication is 
not active and the motor symptoms of PD are present (Limousin et al., 1998). Even 
during “on” periods, PD patients are often impaired by dyskinesia. Due to the decrease in 
responsiveness over time and the progression of the disease, increased doses are often 
necessary to prevent the mild decline in functioning that typically occurs during the first 
few years of drug treatment (Goole & Amighi, 2009). Recent pharmaceutical research is 
focused on slowing down and targeting the release of L-dopa in order to prolong its 
therapeutic effect. Despite side effects and progressive decrease in responsiveness, L-
dopa still remains the most powerful, common, and standard drug treatment for PD 
(Goole & Amighi, 2009). 
 Surgical interventions. Due to the various complications and disadvantages to 
drug treatments such as L-dopa, several surgical interventions have been developed to 
offer patients with PD additional treatment options. Two early ablative procedures that 
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upon investigation did not demonstrate the anticipated effects were thalamotomy and 
pallidotomy (Fox et al., 2011). Some surgical interventions have focused on ways to 
increase dopamine production in vivo (Clarkson, 2001). Examples of these interventions 
include gene therapy and neuronal implantation. Deep brain stimulation is currently the 
most common surgical intervention. Because gene therapy and deep brain stimulation 
were still in the early stages of development when the present study began, they are only 
briefly reviewed below. Further information can be obtained from a search of the medical 
literature on gene therapy and deep brain stimulation as they relate to PD.  
 Gene therapy. Gene therapy has received attention and interest from clinical 
researchers attempting to offer more than palliative care to PD patients (Fiandaca et al., 
2008). Researchers have attempted to convert gene therapy, originally a research tool, 
into a medical option with the potential of altering the course of the disease (Fiandaca et 
al., 2008). To date, there are three “Phase 1 studies” implementing gene therapy that have 
been completed with human subjects in the United States. All of these studies are 
considered to be small safety studies with very small sample sizes totaling just 30 
participants across all three studies. The results from these studies point to the efficacy of 
gene therapy, although consideration must be given to the potential effects of placebo as 
well as the lack of long-term follow-up data available at this time. Two of these studies 
targeted palliative treatment by modifying neurotransmitter levels in the basal ganglia. 
Kaplitt et al. (2007) modified these levels by introducing an adeno-associated viral 
(AAV2) vector containing glutamic acid decarboxylase (GAD) and Eberling et al. (2008) 
examined the introduction of an AAV2 vector containing human aromatic L-amino acid 
decarboxylase (hAADC). The third study by Gasmi et al. (2007) focused on modifying 
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the progression of the disease by delivering a glial-cell-line-derived neurotrophic factor 
(GDNF) homolog to the striatum. Most importantly, results from these studies indicate 
that the participants did not experience any treatment-related adverse side effects. 
Therefore, it can be concluded that the procedure of delivering AAV2 into the basal 
ganglia is relatively practical and safe (Fiandaca et al., 2008). Long-term follow-up 
studies will reveal the efficacy and safety of these gene therapies from a neurological 
perspective (Fiandaca et al., 2008).  
Deep brain stimulation. Deep brain stimulation (DBS) is a surgical intervention 
that attempts to treat the disabling motor symptoms of PD (Limousin et al., 1998). This 
treatment was developed in response to moderate success that was observed in lesion 
procedures like thalamotomies and pallidotomies. DBS procedures have been found to 
produce results as effective as these lesioning procedures, but with fewer adverse side 
effects (Betchen & Kaplitt, 2003). Unilateral pallidotomies are still considered 
efficacious and clinically useful for the treatment of motor fluctuations and dyskinesia 
according to a recent review of PD treatments by Fox et al. (2011). Similarly, unilateral 
thalamotomies are considered to be efficacious and possibly useful as adjuncts to L-dopa 
therapies (Fox et al., 2011). Further review of these two procedures is not within the 
scope of the present study and therefore will not be discussed further. For additional 
information, including clinical implications of the use of pallidotomy and thalamotomy 
with PD patients, please consult the medical literature.  
The DBS procedure involves implanting electrodes bilaterally into the 
subthalamic nucleus of the brain (Limousin et al., 1998). The electrodes are placed by 
stereotactic guidance through imaging and electrophysiologic testing. Once implanted, 
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the electrodes are stimulated through high frequency waves which then result in 
decreased motor disability. Limousin et al. (1998) conducted the first trials of DBS with 
PD patients in 1998. Results from this study revealed improved motor function in patients 
while off medications at a 12-month follow-up. Limousin et al.’s study also demonstrated 
improvements in dyskinesia in patients on medications and improvements in dystonia in 
patients off medications following DBS.  
 Krack et al. (2003) examined the long-term effects of bilateral stimulation of the 
subthalamic nucleus in 49 PD patients over the course of five years. This study concluded 
that patients exhibited marked improvements in motor function while off medications and 
in dyskinesia while on medications. Specifically, improvements in tremor, rigidity, 
akinesia, gait, and postural stability were sustained over five years (Krack et al., 2003). 
Speech was the only motor function that did not demonstrate improvement at the five-
year follow-up assessment. Many other studies have demonstrated similar improvements 
at long-term follow-up of DBS (Rodriguez-Oroz et al., 2004; Visser-Vandewalle et al., 
2005). To date, thousands of patients with advanced PD have now undergone DBS in 
facilities around the world (Antoniades, Carpenter, & Temel, 2012). Due to the 
encouraging results of long-term follow-up studies such as Krack et al.’s (2003), DBS is 
considered by many to be the surgical intervention of choice for PD patients.  
 Neural implantation. In addition to drug and surgical interventions, neural 
implantation has been another intervention that has been investigated with PD patients. 
Neural implantation involves replacing dopamine-producing neurons in the substantia 
nigra so that these cells will release dopamine properly and “show the molecular, 
morphological, and electrophysiological properties of substantia nigra” (Lindvall et al., 
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2004, p. S43). Two types of neural implantation are stem cell implantation and fetal 
tissue implantation.  
 Stem cell implantation surgery. Stem cells, or “clone forming, self-renewing, 
pluripotent, progenitor cells,” are highly valuable sources of implantation material in a 
variety of clinical settings and in a variety of diseases (Rice, Halfpenny, & Scolding, 
2003, p. 351). While it is a complex task to replace cells lost through disease processes in 
attempt to induce functional recovery, animal research has demonstrated that replacement 
of neurons and reconstruction of damaged neuronal circuitry is possible (Lindvall et al., 
2004). Moreover, evidence suggests that symptom reduction can occur in diseased 
patients following cell replacement (Lindvall et al., 2004). Research on stem cell 
implantation has given priority to studies with neurological diseases due to the few 
available treatments and the devastating progression of these diseases (Rice et al., 2003).  
 While stem cell implantation exhibits high potential for the treatment of PD 
symptoms, there are many areas that deserve further development. Lindvall et al. (2004) 
argued that selection criteria for appropriate candidates for stem cell implantation needs 
to be developed in order to identify those who are likely to benefit the most. Specifically, 
patients whose primary pathology is focused on the deterioration of dopamine neurons 
are better candidates than those who have pathological changes in systems not related to 
dopamine (Lindvall et al., 2004). Next, advancements related to the “dose” and location 
of grafts must be made in order to improve their functional efficacy. Lastly, 
developments in stem cell implantation must be explored in order to decrease the chance 




 Fetal tissue implantation surgery. A second form of neuronal implantation that has 
been used in the treatment of PD is fetal tissue implantation. The best results of fetal 
tissue implantation have come from studies where dopaminergic neurons have been 
derived from human fetal ventral mesencephalon (Clarkson, 2001). Lindvall et al. (1989) 
conducted the first study exploring human fetal tissue implantation with PD patients. 
Since then, implantation surgeries have generally demonstrated improvements in motor 
skills and lowered the required doses of L-dopa for some patients (Clarkson, 2001). 
Specifically, in his review of clinical studies using fetal tissue implantation, Clarkson 
(2001) determined that around two-thirds of patients demonstrate moderate improvement 
in motor function following surgery and, therefore, report improved quality of life. 
Nevertheless, these clinical studies have produced variable results due to the low survival 
of dopamine cells after implantation. Studies have suggested that as few as 5% of the 
dopamine cells survive implantation (Clarkson et al., 2001; Zawada et al., 1998). 
Researchers have concluded that the number of years since the onset of the disease does 
not predict the benefit of implantation as it relates to motor skills or L-dopa dose due to 
the fact that positive results have been observed in patients with differing years of onset, 
ranging from five to 15 years (Clarkson, 2001). Similarly, implantation benefit has been 
found to appear within the first six months following surgery and an increase in benefit 
may be observed for somewhere between two and six years (Clarkson, 2001; Yuan et al., 
2010). However, there is no evidence suggesting when the benefit of implantation will 
reach optimal performance or what the trajectory of improvement or decline is.  
 In addition to some of the adverse side effects that have been shown to accompany 
fetal tissue implantation, such as dystonia and dyskinesia, there are also limitations in 
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terms of the ethical, political, and social issues and implications related to using the tissue 
from aborted fetuses (Yuan et al., 2010). A discussion of these issues is beyond the scope 
of the present study and therefore will not be explored here. Additional information 
related to these arguments can be found in the most recent literature on fetal tissue and 
stem cell implantation. 
 Results from the parent study. The National Institute of Health (NIH) has funded 
two double-blind clinical trials examining the effects of fetal tissue implantation in 
patients with PD (Clarkson, 2001). The goal of these studies was to demonstrate the 
benefit of fetal tissue implantation over controls and to explore which patients benefit the 
most from surgical intervention (Clarkson, 2001). The first of these two NIH funded 
studies was conduced by Freed et al. (2001), and is the parent study and participant 
sample used in the analyses of the present study. In this study, 40 patients with severe PD 
were selected to receive either an implant of human embryonic dopamine neurons or a 
sham surgery, with 20 patients in each group (Freed et al., 2001). The study followed a 
double-blind procedure that was maintained for 12 months. Specifically, mesencephalic 
tissue from four embryos was implanted bilaterally into the putamen of the 20 patients in 
the treatment group. Those patients in the control group received a sham surgery, during 
which holes were drilled into their skulls without penetrating the dura (Freed et al., 
2001). At a 12-month follow-up, those patients who received the sham surgery had not 
improved. In 65% of the patients who received the actual fetal tissue implantation, 
positron emission tomography (PET) scans showed that there was an observable 20% 
increase of dopamine activity in the putamen. Additionally, implant recipients under 60 
years old demonstrated a significant decrease in symptoms, particularly motor symptoms, 
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while older patients demonstrated little to no improvement 12 months after surgery. 
Unfortunately, dystonia and dyskinesia developed in 15% of the implant recipients at 12-
month follow-up (Freed et al., 2001).  
 The second study by Olanow et al. (2003) examined the effects of fetal tissue 
implantation in 34 patients with advanced PD. The patients were followed for 24 months 
and the study was double-blind with a placebo control group (Olanow et al., 2003). 
Olanow et al. concluded that there was not a significant treatment effect or a significant 
difference between the treatment and control group on a variety of motor symptoms as 
measured by the Unified Parkinson’s Disease Rating Scale (UPDRS). Nevertheless, the 
study did demonstrate that patients with fewer motor symptoms at the start of the study 
received some benefit following the implantation (Olanow et al., 2003). 
 While the results from the parent study, Olanow et al. (2003), and others using 
fetal implantation have limitations, many authors argue that this is not reason to 
discontinue studies investigating the use of fetal tissue in PD patients (Betchen & Kaplitt, 
2003; Fox et al., 2011). Suggestions have been made to develop a more targeted 
implantation as well as to determine the appropriate therapeutic window to increase 
dopamine levels without inducing dyskinesias (Betchen & Kaplitt, 2003).  
Placebo Effect 
 The placebo effect is a phenomenon that has been studied in numerous scientific 
and clinical fields for many years (Price, Finniss, & Benedetti, 2008). It has been of 
particular interest and debate in the medical field due to the clinical implications of 
placebo trials and interventions. Generally, placebos have been defined as “agents or 
procedures aimed at pleasing the patient rather than exerting a specific effect” (Price et 
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al., 2008, p. 567). Improvements associated with placebos have been demonstrated in 
multiple sclerosis, pain disorders, and many neurological disorders. However, these same 
placebo-associated improvements have been questioned in other non-neurological 
disorders such as obesity, asthma, nausea, and hypertension (Hróbjartsson & Gøtzsche, 
2001). Since the placebo effect was first formally studied in 1799, researchers and 
technology have identified many of the neurobiological and psychological mechanisms 
that operate in the placebo phenomenon (Colloca & Benedetti, 2005; Price et al., 2008). 
The placebo response has typically been defined as the change that occurs in symptoms 
or conditions in patients following the administration of a placebo. A response of this 
kind can only be considered a true placebo response when it occurs in the context of an 
experimental design when the placebo condition is compared to an untreated baseline 
group otherwise referred to as the “natural history group” (Price et al., 2008, p. 567).     
  Psychosocial and environmental determinants. Efforts have also been made to 
examine the psychosocial and environmental context that surround the patient and how 
this context may affect the placebo response through influences on the “patient’s 
expectations, desires, and emotions” (Price et al., p. 567). These contextual factors 
include processes such as classical conditioning, verbal persuasion, past experiences with 
treatments, and behaviors exhibited by the patients’ healthcare providers and primary 
supports. Naturally these contextual factors vary depending on the conditions of the study 
or the clinical situation. Given the range and magnitude of these factors, influence on the 
placebo response itself is variable as well (Colloca & Benedetti, 2005). This variability 
can be seen in the range of placebo effect sizes observed among studies of pain 
treatments, an area that has examined the placebo effect extensively (Vase, Riley, & 
 
29 
Price, 2002). However, attempting to assess the magnitude of the placebo effect and, in 
particular, making conclusions about the proportion of patients that respond to placebos 
is a difficult task. Nevertheless, the fact that some patients respond to placebos and others 
do not is known (Price et al., 2008).   
 Cognitive and emotional determinants. Similar to the way psychosocial and 
environmental factors influence the presence and magnitude of the placebo response, 
cognitive and emotional factors have been found to contribute as well (Price, et al., 
2008). These cognitive and emotional factors include expected symptom intensity, 
desired symptom change, emotional change, and memory distortions. To illustrate, 
patients may expect to achieve a certain level of pain relief from a treatment, and this 
expectation can ultimately influence the placebo response. Likewise, a memory of past 
pain experience, or more generally symptom intensity, can influence expectations of 
future pain experiences and indirectly affect the placebo response (Price et al., 2008). 
Related to expectations of symptom intensity is the desire for a specific change in 
symptom. Desire, or “the experiential dimension of wanting something to happen or 
wanting to avoid something happening,” is likely associated with the placebo 
phenomenon (Price et al., 2008, p. 572). One study by Vase et al. (2004) demonstrated an 
interaction between desire for pain reduction and expected pain intensity. Specifically, 
these two factors contributed to pain analgesia and this model accounted for 38% of the 
variance observed in the placebo response (Vase et al., 2004).  
One last construct that can moderate the influence of these cognitive and 
emotional factors and ultimately the placebo response is somatic focusing (Price et al., 
2008). Somatic focusing has been found to function as a source of feedback of the 
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placebo effect. In other words, when patients attend to signs of physical improvement, it 
is viewed as evidence of the effectiveness of the placebo treatment that further increases 
the magnitude of the placebo response over time (Geers, Helfer, Weiland, & Kosbab, 
2006). Other psychological processes may mediate a placebo response that is more 
unconscious, such as classical conditioning. For example, patients may develop 
conditioned physiological responses to the presence of conditioned stimuli, such as a pill 
or syringe. To conclude, there are a variety of mechanisms and conditions that underlie 
and influence the placebo response (Price et al., 2008). The mechanisms of self-efficacy 
and social support in relation to the placebo response will be explored later in this chapter 
after providing a discussion of each of these constructs independently.  
 Neurobiological influences. Studies examining the change in brain activity that 
occur as a function of the placebo effect have found reductions in neural activity in areas 
that process experiences of anxiety and pain (Price, et al., 2008). These reductions have 
also been found to occur with increases in neural activity in brain areas that are 
associated with emotion regulation. Dopamine release is involved in these pathways 
along with opioid and serotonergic mechanisms in the brain (Goetz et al., 2008). 
Generally, this research indicates that placebo responses are produced through processes 
of reward and aversion in conjunction with the associated neural activity in the brain 
(Price et al., 2008).  
 Placebo effect and surgical procedures. Sham surgeries have been used to study 
the therapeutic benefits of a surgical intervention as well as to explore the placebo 
response (Birch, 2006). These sham surgeries have been conducted in clinical trials with 
a variety of medical patients. As aforementioned, the use of a placebo or sham surgery 
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was part of the design of the parent study, from which the current study is derived. These 
sham surgeries are known to be associated with strong placebo effects (Birch, 2006). 
There are many explanations for what factors contribute to the placebo response 
following sham surgeries. Birch (2006) discussed the following explanations in his 
review of the placebo effect in medical procedures: minimal expectation to provide 
evidence for the treatment’s efficacy, the physical discomfort from the surgery, the 
meaning associated with the surgery, and the effects attributed to the loss of blood during 
the procedure. Generally, all of these explanations suggest that there are biological 
changes and effects that occur during sham surgeries that must be considered in the 
interpretation of a placebo response (Birch, 2006). A more complete discussion of the 
biological effects associated with sham surgeries can be found in the medical literature, 
as it is outside the scope of the current study.  
 Placebo effect and PD. Placebo trials have been used to study many new 
therapies for PD and have become a standard component of these clinical trials (Goetz et 
al., 2008). As previously mentioned, the placebo response is associated with motivation, 
reward, and response to novel stimuli and therefore neural pathways associated with 
dopamine activation are involved. Because of the diminished supply of dopamine in the 
neural pathway of PD patients, placebo treatments have focused on this patient 
population (Goetz et al., 2008). The placebo response has been studied in both medical 
and surgical trials with PD patients, and its effects have been examined in a range of 
disease symptoms. In a review of 11 medical and surgical placebo trials with PD patients, 
Goetz et al. (2008) found that the overall placebo response rate was 16% with a range of 
0% to 50% of patients. This review found that some of the lowest placebo response rates 
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occurred in clinical trials examining disease modification in patients who did not have a 
need for symptomatic treatment (Goetz et al., 2008). Improvements in motor fluctuations 
appear to occur most often in medication trials compared to other target symptoms in PD 
patients. Lastly, surgical interventions appear to demonstrate the highest placebo 
response rates, though they typically had smaller sample sizes (Goetz, et al., 2008). 
According to Goetz et al.’s (2008) review, a positive placebo response does not appear to 
be associated with age, gender, PD duration, or baseline Hoehn and Yahr stage (a scale 
used to measure disease stage in PD patients).  
 Improvements associated with placebo treatments have been documented in 
relation to many of the cardinal symptoms of PD, but placebo responses in dyskinesia 
have not been well-studied. Goetz and Laska et al. (2008) examined the effects of a drug 
trial of Sarizotan and placebo on dyskinesia. The overall findings of their study suggest 
that dyskinesias are affected by placebo treatments (Goetz, Laska, et al., 2008). These 
positive changes in dyskinesias were not associated with changes in other PD symptoms.  
 Another study by Mercado et al. (2006) examined the placebo response to deep 
brain stimulation in PD patients’ motor scores according to the Unified Parkinson’s 
Disease Rating Scale (UPDRS III). The results from this study suggest that expectation 
and placebo response were significant predictors of change in motor scores of PD 
patients (Mercado et al., 2006). Specifically, the authors concluded that the placebo was 
particularly effective on bradykinesia but was not found to significantly change scores in 
tremor or rigidity (Mercado et al., 2006). As newer treatments are developed and made 
available for PD patients, such as DBS, it can be expected that the placebo response will 
continue to be a phenomenon studied by clinical researchers.  
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Within the present study, the mechanisms by which the placebo effect operated 
were of importance. Because several psychosocial, environmental, cognitive, and 
emotional determinants have been found to influence the presence and magnitude of the 
placebo effect, the mechanisms of specific variables within each of these domains have 
been examined (Price et al., 2008). Two such variables within the social and cognitive 
domains that may be related to the placebo effect are self-efficacy and social support 
(Crow et al., 1999; Kaptchuck et al., 2008; Miller, Colloca, & Kaptchuck, 2009). These 
two constructs will be discussed independently in this chapter followed by a discussion 
on the relationships between each and the placebo effect.  
Self-efficacy 
 Definition of self-efficacy. Albert Bandura (1997) has consistently defined 
perceived self-efficacy as “beliefs in one’s capabilities to organize and execute the 
courses of action required to produce given attainments” (p. 3). Perceived self-efficacy, 
henceforth referred to as self-efficacy, affects the courses of action individuals choose to 
follow, the effort they put forth, and the way they will persevere when confronted with 
obstacles (Bandura, 1997). Additionally, self-efficacy influences resilience to adversity, 
thought patterns, experience of stress, and level of accomplishment. Self-efficacy is an 
essential component of personal agency and therefore a major basis of action and human 
behavior (Bandura, 1997). Bandura (2012) explains that within this self-belief system 
“people’s beliefs in their capabilities vary across activity domains and situational 
conditions rather than manifest uniformly across tasks and contexts in the likeness of a 
general trait” (p. 13). This is unlike related concepts, such as self-esteem, self-confidence, 
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and locus of control, as these concepts exist as more general natures or traits (Maibach & 
Murphy, 1995).  
 Self-efficacy and social cognitive theory. Social cognitive theory describes a 
casual structure that addresses how people develop competencies and regulate actions 
(Bandura, 1986). This structure consists of a triadic reciprocal causation in which “human 
functioning is a product of the interplay of intrapersonal influences, the behavior 
individuals engage in, and the environmental forces that impinge upon them” (Bandura, 
2012, p. 11). The presence of these intrapersonal influences suggests that individuals can 
exert intentional influences over their lives and events that take place. In other words, 
they are active agents in their lives. Self-efficacy is considered to be one of these 
intrapersonal constituents (Bandura, 1986). It is through different forms of agency that 
people exercise influence on their lives. When individuals influence the conditions that 
are in their direct control, this is referred to as personal agency. In many contexts, 
individuals do not have direct control over events that affect them (Bandura, 1997, 2000). 
They must influence others that have the knowledge, means, or resources to attain the 
desired outcome or exercise proxy agency. The last form of agency refers to collective 
agency when individuals work together, combining skills, knowledge, and resources to 
achieve a desired outcome. Individuals operating within a forum of collective agency 
may have diverse self-interests but can still work toward a common purpose (Bandura, 
1997, 2000). 
Sources of self-efficacy. Peoples’ beliefs in their capabilities are developed from 
four different sources: mastery experiences, social modeling, social persuasion, and 
physical and emotional states (Bandura, 1997). The first source of self-efficacy, mastery 
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experiences, comes from one’s practical experience of success or accomplishment. When 
individuals experience frequent failure, particularly early on in the learning process, self-
efficacy often decreases in that specific domain. However, if successes come too easily 
and quick results are expected, one may become discouraged by the experience of failure 
(Bandura, 2012). Therefore in order to develop resilient self-efficacy, individuals must 
experience accomplishments in the face of obstacles with “perseverant effort” (Bandura, 
2012, p. 13). Bandura (2012) explains that resilience is “built by learning how to manage 
failure so that it is informative rather than demoralizing” (p. 13). Mastery experiences are 
the most influential and important source of self-efficacy as they provide the most direct 
and authentic information about one’s capabilities to succeed (Bandura, 1997).   
The second source of self-efficacy comes from social modeling or observation of 
others (Bandura, 2012). Observing others as they succeed in similar contexts can provide 
information to one’s own ability to successfully perform in the same context. During 
social modeling, it is important that those being observed share similar characteristics to 
those observing (Bandura, 1997). These observations serve as indicators to measure one’s 
own capabilities and ultimately estimate the likelihood of success. Social modeling is 
considered to be a weaker source of self-efficacy than direct experience, but nevertheless 
is a mode of influence (Bandura, 1997).  
Social persuasion is the third source of influence on self-efficacy. Individuals can 
be persuaded by significant others that they possess the necessary capabilities to master a 
given task (Bandura, 1997). Persuasion can be particularly effective if individuals harbor 
self-doubts about their capabilities and can support perseverance when difficulties arise 
(Bandura, 2012).  
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The fourth source of self-efficacy relies on information from one’s physical and 
emotional states. These types of somatic indicators are of particular importance in 
domains involved with “physical accomplishments, health functioning, and coping with 
stressors” (Bandura, 1997, p. 106). Physiological indicators may come from experiences 
of autonomic arousal, fatigue, or pain, which are indicative of physical inefficacy. 
Similarly, mood states, such as anxiety or depression, can provide individuals with 
information from which to judge their personal efficacy (Bandura, 1997). Therefore, 
enhanced physical status, reduced levels of stress and negative emotionality, and correct 
interpretations of bodily states can positively influence one’s sense of self-efficacy in 
related domains (Bandura, 1997).  
In developing a judgment about one’s capabilities in a given domain, integration 
of information from all four of these sources is required. The weight that each domain is 
given is dependent on the specific domain being assessed as well as each individual’s 
integration rules (Bandura, 1997). Various cognitive processes are involved in integrating 
all of this information in order to form the self-concept of efficacy. These self-appraisal 
skills are developed through the growth of self-reflective meta-cognitive skills that 
examine “the adequacy of one’s self-assessments” (Bandura, 1997, p. 115).  
Mediating processes. The effects of self-efficacy are mediated through a variety 
of processes. Social cognitive theory specifies a theory of learning that works through 
four main processes: selective, motivational, cognitive, and affective (Bandura, 1997). 
These processes assist in explaining how self-efficacy beliefs produce their effects. 
Selection processes refer to the decisions that individuals make about which activities 
they choose to engage in, or choice behavior (Bandura, 1997). These decisions are 
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informed by one’s beliefs about his or her capabilities to perform that specific activity. In 
other words, one’s perceived self-efficacy. Often individuals avoid tasks that they 
perceive exceed their capabilities and seek out tasks that they are confident they can 
perform instead (Bandura, 1977, 1986). Motivational processes refer to the beliefs 
individuals form about perceived capabilities of what they can do, anticipation of 
outcomes, goal setting, and planning courses of action (Bandura & Cervone, 1983). 
Motivation is often stronger when individuals believe they can reach their goals. 
Similarly, those with high levels of self-efficacy often demonstrate more perseverance to 
overcome obstacles than those with lower levels (Bandura & Cervone, 1983). In regard to 
cognitive processes, self-efficacy can affect thought patterns that encourage or discourage 
performance in a certain activity. These cognitive processes can therefore affect the 
determination of goals or aspirations, the visualization of performance outcomes, and 
quality of analytical thinking (Bandura, 1995; Maibach & Murphy, 1995). Lastly, self-
efficacy has been found to regulate emotional states. The beliefs individuals hold about 
their capabilities to cope with threatening or difficult situations can affect how much 
distress they experience (Bandura, 1995). For example, those with high levels of self-
efficacy manage to lower stress and anxiety by engaging in behaviors that reduce the 
present threat in their environment. Contrarily, low levels of self-efficacy across multiple 
domains can lead to depression (Bandura, 1995). In summary, self-efficacy affects the 
behavior individuals choose to engage in, the effort and persistence they put forth in an 
activity, their thought patterns, and emotional states. The quality of psychosocial 
functioning is greatly impacted by self-efficacy (Bandura, 1986). 
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Measurement of self-efficacy. In many empirical studies, self-efficacy is often 
erroneously treated as a generalized trait. Bandura (1997) explains that one’s efficacy 
varies across domains of functioning, but also varies within certain aspects of a single 
domain. Therefore appropriate measurement of self-efficacy “relies on a good conceptual 
analysis of the relevant domain of functioning” (Bandura, 2006, p. 310). Bandura (2012) 
argues that self-efficacy should be measured on a unipolar scale, ranging from zero to 
some maximum level of belief. He argues for this unipolar scale as opposed to a bipolar 
scale with negative gradations since individuals cannot possess a level of self-efficacy 
that is less than completely inefficacious, or zero. Similarly, Bandura explains that 
attempting to measure a “neutral” level of self-efficacy is meaningless, and instead a 
midpoint on a unipolar scale should be referred to as a moderate level of self-efficacy. 
Bandura (2012) also recommends that the wording of self-efficacy items use “can do” as 
opposed to “will do.” The statement “will do” most accurately refers to one’s intention to 
perform a task, not one’s belief that they have the capabilities to perform that task 
(Bandura, 2012). Moreover, efficacy scales with multiple gradations are considered to be 
more sensitive and reliable than those with few response options (Pajares, Hartley, & 
Valiante, 2001). 
For many years, Bandura (1977) also described three measurable dimensions of 
the concept of self-efficacy: magnitude, strength, and generality. The domain of 
magnitude refers to the perceived difficulty of adopting a behavior. Strength relates to the 
level of certainty one has in his or her ability to perform a specific activity. And lastly, 
generality reflects the degree to which efficacy beliefs are related to other behavioral 
domains as well as across time (Bandura, 1977). 
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Recently, Bandura (2012) discussed the common misconstrual of self-efficacy as 
specific tasks when researchers are intending to assess activity domains. For example, 
measuring self-efficacy in academic achievement requires the measurement of a large 
scope of performances within this activity domain, not just one specific task. Self-
efficacy is then the total score of all the items used to assess the activity domain, in this 
case academic achievement, rather than a specific item (Bandura, 2012). Frequently, self-
efficacy measures have been “mischaracterized” as “highly specific and narrow in 
scope,” which is a misunderstanding of how to measure the construct (Bandura, 2012, p. 
17).  
Self-efficacy and health functioning. A number of studies have examined the 
influential role of self-efficacy in a range of health-related behaviors. Specifically, self-
efficacy has been explored in the context of health promotion behaviors, reduction of 
health risk behaviors, and self-management of chronic disease (Lorig, Mazonson, & 
Holman, 1993; Schwarzer & Fuchs, 1995). The health behaviors examined in the 
literature are comprehensive: condom use, smoking cessation, healthy dieting, exercise, 
and preventative health behaviors such as cancer screenings (Schwarzer & Fuchs, 1995). 
These studies have consistently demonstrated that perceived self-efficacy is an essential 
component in regulating the “adoption of health promoting behaviors and the elimination 
of health impairing behaviors” (Schwarzer & Fuchs, 1995, p. 281). Moreover, the 
literature illustrated that self-efficacy influences the process of behavior change at 
various stages across the decision-making, initiation, and maintenance processes 
(Schwarzer & Fuchs, 1995).  
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In relation to chronic disease, the literature has established that self-efficacy to 
carry out self-management activities greatly improves the beneficial outcome of these 
practices (Lorig et al., 2001). Like the literature on health promotion and risk reduction 
behaviors, self-efficacy has been examined in the context of many chronic diseases such 
as heart attack recovery, chronic obstructive pulmonary disease, diabetes, chronic 
arthritis, chronic pain, organ transplants, and breast cancer (as cited in Holman & Lorig, 
1992). Many of these studies investigated perceived self-efficacy to perform activities 
related to self-management or self-care. For example, diet, exercise, and medication 
management are a few common domains of activities that comprise self-management of 
chronic disease. Given the unique nature of activities involved with self-management in 
each specific chronic disease, researchers have developed questionnaires of self-
management self-efficacy that are tailored to their disease of interest. Self-efficacy has 
been given much attention because it is one of the few factors related to chronic disease 
management that is amenable to change. Therefore, interventions have been developed to 
increase self-efficacy in the chronic disease population. As Lorig et al. (1993, 2001), 
Weng, Dai, Huang, and Chiang (2010), Davis, Carrieri-Kohlma, Janson, Gold, and 
Stulbarg (2006), and several other researchers have asserted, and in line with Bandura’s 
(1997) theory of self-efficacy, individuals are more likely to effectively manage their 
chronic disease if they feel confident in their capacity to self-manage.        
Self-efficacy and self-management of PD.  Few studies have examined the role 
of self-efficacy in the management of PD. One such study by Chenoweth et al. (2008) 
examined the role of various factors, including self-efficacy, in self-management with a 
group of individuals with moderate to advanced stages of PD following an acute illness 
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event. This study found that self-efficacy predicted better self-management in individuals 
with PD and also demonstrated that familial support was associated with higher levels of 
self-efficacy (Chenoweth et al., 2008). These findings are consistent with those of 
another study by Peteet (2002), which demonstrated that both formal and informal 
support can be found to enhance self-efficacy and self-management in individuals with 
PD (as cited in Chenoweth et al., 2008).  
A similar study conducted by Montgomery et al. (1994) explored the benefits of a 
program designed to promote health and educate patients with PD. The program had a 
variety of objectives: “improve health confidence, provide information and support, 
improve physical function through exercise, and work with the physician to optimize 
medical treatment compliance” (Montgomery, et al., 1994, p. 429). A total of 290 PD 
patients, 140 in the treatment group and 150 in the control group, participated in this 
intervention that was delivered via post mail. Montgomery et al. (1994) found that the 
treatment group demonstrated increased levels of exercise, reduced side effects, 
decreased “off” times in their L-dopa treatment, decreased summary scores on an overall 
measure of PD symptoms, and reduced doctor visits, hospital stays, and overall sick days 
when compared to the control group. Furthermore, Montgomery et al. (1994) found that 
the treatment group exhibited improvements in overall quality of life and self-efficacy 
scores. Montgomery et al. (1994) interpreted the improvements observed in the treatment 
group to have occurred through the mechanisms of increased exercise and increased 
levels of self-efficacy.  
While sparse, findings from these studies provide evidence for the beneficial 
effects of high levels of self-efficacy on management of PD. They further offer 
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justification for the examination of self-efficacy in this patient population, particularly 
throughout the implementation of a medical intervention.  
Social Support 
 Definition of social support. Social support is an important construct that 
influences the placebo response, health outcomes, and levels of perceived self-efficacy 
(Chenoweth et al., 2008; Miller, Colloca, & Kaptchuck, 2009; Kaptchuck et al., 2008; 
Kaşikçi & Alberto, 2007; Penninx, Kriegsman, van Eijk, Boeke, & Deeg, 1996). Social 
support has been defined as “the perception or experience that one is loved and cared for 
by others, esteemed and valued, and part of a social network of mutual assistance and 
obligations” (Wills, 1991 as cited in Taylor, 2003). Social support is a concept that has 
been widely studied in the psychological and medical literature in a variety of patient 
populations. Social support can be provided in many different forms, such as 
informational support, instrumental support, and emotional support (Taylor, 2003; 
Uchino, 2004). These various forms of social support are typically examined in terms of 
coping with a particular stressor. Due to the broad range of benefits that have been 
associated with social support, it has been studied extensively.   
 Several theoretical models have been developed to conceptualize social support 
(Cutrona & Russell, 1987). Robert Weiss’s model of social provisions is one framework 
that has been considered by Cutrona and Russell (1987) to incorporate many of the major 
elements included across several conceptualizations of social support (as cited in Cutrona 
& Russell, 1987). Cutrona and Russell (1987) developed the Social Provisions Scale 
based on Weiss’s six functions of social relationships, and it is the measure that was used 
to assess social support in the present study. Weiss’s (1974, as cited in Cutrona & 
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Russell, 1987) model explains that relationships with others can serve six different 
provisions or functions. These six provisions are classified into two conceptual 
categories, “assistance-related” and “non-assistance-related” (Weiss, 1974, as cited in 
Cutrona & Russell, 1974). Within the assistance-related category, Weiss (1974, as cited 
in Cutrona & Russell, 1987) described the function of guidance, which typically comes in 
the form of advice or information from teachers or mentors, and reliable alliance, which 
is often provided by family members who can be depended upon for tangible assistance. 
In the non-assistance-related category, Weiss (1974, as cited in Cutrona & Russell, 1987) 
discussed the provisions of reassurance of worth, opportunity for nurturance, attachment, 
and social integration. Reassurance of worth is the recognition of one’s competence and 
value by others (Weiss, 1974, as cited in Cutrona & Russell, 1987). This kind of social 
provision can bolster one’s self-efficacy and ability to cope with stress more effectively 
(Cutrona & Russell, 1987). Weiss (1974, as cited in Cutrona & Russell, 1987) described 
the next social provision, opportunity for nurturance, as a sense that one is relied upon by 
others. While this provision cannot be considered social support, Cutrona and Russell 
(1987) discuss how this provision is an important aspect of interpersonal relationships 
that can enhance health and well-being. The fifth social provision is attachment, or the 
existence of a close relationship that provides emotional closeness and a sense of 
security. The sixth and final provision in Weiss’s (1974, as cited in Cutrona & Russell, 
1987) model of social provisions is social integration which refers to a sense of belonging 
to a group of individuals who have a shared interest (Weiss, 1974, as cited in Cutrona & 
Russell, 1987). The positive affects of each of these social provisions may assist in 
promoting health and well-being (Cutrona & Russell, 1987).   
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Two different hypotheses have been developed to assist in describing how and 
under what circumstances social support operates. The first of these hypothesis is the 
“direct effects hypothesis”, which contends that social support is generally beneficial to 
both physical and psychological health during stressful and non-stressful times (Taylor, 
2003). The second hypothesis is called the “buffering hypothesis” and argues that social 
support is keenly beneficial to overall health during stressful times but does affect health 
during non-stressful times. Specifically, the buffering hypothesis maintains that social 
support serves as a buffer to stress which ultimately allows an individual to handle stress 
more effectively (Taylor, 2003; Uchino, 2004). To date, research examining this concept 
has demonstrated evidence for both hypotheses and continues to support the conclusions 
from a classic work by Cohen and Wills (1985). Cohen and Wills (1985) have suggested 
that both conceptualizations of social support are evident, but the processes through 
which social support operates are different for each hypothesis. Specifically, the direct 
effect of social support is evident when measuring the level of integration into a social 
network. On the other hand, the buffering hypothesis is apparent when measuring the 
“perceived availability of interpersonal resources that are responsive to the needs elicited 
by stressful events” (Cohen & Wills, 1985, p. 310).  
 Social support and health functioning. In terms of psychological benefits, 
social support has been found to reduce depression and anxiety in times of stress (Lin, 
Ye, & Ensel, 1999). Moreover, social support has been found to enhance psychological 
adjustment to a variety of chronic diseases such as coronary artery disease (Holahan, 
Moos, Holahan, & Brennan, 1997), cancer (Penninx et al., 1998), and stroke (Robertson 
& Suinn, 1968). Social support has also been found to reduce cognitive decline in older 
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adults (Seeman, Lusignolo, Albert, & Berkman, 2001). Lastly, social integration has an 
impact on mortality, as those with higher levels of support have a lower risk of death 
(Seeman, 1996). In a hallmark study conducted by Spiegel, Bloom, Kraemer, and 
Gottheil (1989), individuals with metastatic breast cancer were found to have longer 
survival rates than controls after participating in supportive group therapy.  
 Interestingly, the use of one’s social support system is not necessary to reap its 
benefits. In fact, research has demonstrated that simply the perception of support can be 
stress-reducing and beneficial (Taylor, 2003; Thoits, 2011; Uchino, 2004). Penninx et al. 
(1996) performed a literature review on the effects of social support on chronic disease 
and concluded that the perception of social support is of greater importance than 
functional or structural support. Regardless of the type of chronic disease, positively 
perceived social support has been found to have favorable effects on the course of the 
disease (Barron, Cutrona, Hicklin, Russell, Lubaroff, 1990; Penninx et al., 1996; Uchino, 
2004). Penninx et al. (1996) also concluded that the benefits of perceived social support 
extended to “psychological adjustment, well-being, functional status, and also more 
‘objective’ health outcomes” (p. 223). In 1998, Penninx et al. examined the effects of 
social support, as measured by aspects of structural and functional support defined by the 
researchers, on coping with depressive symptoms in a group of participants with chronic 
diseases. Their study found that there were favorable effects of social support, 
particularly having a partner or close relationships, on depressive symptoms (Penninx et 
al., 1998). Similarly, Kahn, Hessling, and Russell (2003) explored the relationship 
between social support, negative affectivity, physical health, and well-being, specifically, 
depression symptoms, loneliness, and life satisfaction, in a sample of older adults. Their 
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study found that perceived social support, as measured by The Social Provisions Scale 
(Cutrona & Russell, 1987), was a strong predictor of well-being after controlling for 
negative affectivity (Kahn et al., 2003).  
 Social support has also been examined in the context of commitment to medical 
regimens. Specifically, Resnick, Orwig, Magaziner, and Wynne (2002) have suggested 
that adherence to an exercise program in a group of older adults was indirectly enhanced 
by the presence of social support, as measured by The Social Support for Exercise Habits 
Scale (Sallis et al., 1987) as it strengthened self-efficacy and outcome expectations. In 
summary, social support has been studied extensively and results consistently 
demonstrate a beneficial effect on chronic disease and health-promoting behaviors.  
 Social support in PD.  In light of the demonstrated beneficial effects of perceived 
social support on chronic disease, this construct has been examined in patients with PD as 
well. The literature has consistently demonstrated that social support is related to positive 
health outcomes in PD patients (Brod, Mendelsohn, & Roberts, 1998; Ehman, Beninger, 
& Gawel, 1990; McRae et al., 2011). Studies have examined outcomes in terms of both 
physical and psychosocial health. A recent study by Simpson, Haines, Lekwuwa, Wardle, 
and Crawford (2006) examined the effects of social support on psychological functioning 
in 34 PD patients. Simpson et al. (2006) measured social support with a comprehensive 
approach by quantifying the presence of close relationships as well as examining the 
satisfaction with social support through the social support subscale of the Parkinson’s 
Disease Questionnaire (PDQ-39); (Jenkinson, Fitzpatrick, Peto, Greenhall, & Hyman, 
1997). This study found that as levels of satisfaction with social support decreased, scores 
on depression, anxiety, and overall stress increased (Simpson, et al., 2006). Additionally, 
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this study revealed that positive affect was associated with quantitative measures of social 
support such as the total number of close relationships (Simpson et al., 2006). The 
relationships observed in this study were discussed in the context of clinical implications 
in psychotherapeutic treatment for PD patients.  
 Another study by Schreurs, De Ridder, and Bensing (2000) explored the role of 
coping and social support on quality of life in PD patients. Schreurs et al. (2000) 
measured received social support in their sample with the Social Support List (SSL-I) 
(Kempen & Van Eijk, 1995). The study concluded that passive coping styles were related 
to problems in the domains of physical, psychological, and social functioning (Schreurs 
et al., 2000). However, the adverse effects of passive coping did not extend to patients’ 
overall functioning at one-year follow-up. In opposition to their research hypothesis, 
Schreurs et al. (2000) did not find that quality of life was affected by patients’ attempts to 
seek support or the support they actually received. These results are in contrast with most 
other studies that demonstrate improved functioning and quality of life with greater social 
support (as cited in Schreurs et al., 2000). Schreurs et al. (2000) suggested that this 
finding may have resulted from a bias in their sampling method, as all of the patients 
studied were self-referred from a patient organization and, therefore, perhaps less likely 
to be isolated. In other words, these patients already had high levels of social support in 
their lives. The study did conclude that negative social interactions were associated with 
problems in psychological functioning (Schreurs et al., 2000). 
 A comprehensive study conducted by Backer (2000) examined illness-related 
stressors in 70 PD patients and the role of social support and coping style in physical and 
psychosocial health dysfunction. The illness-related stressors that were examined 
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included losses in functional abilities (difficulty getting out of bed and getting up from a 
chair, falls, inability to drive, etc.) as well as stressors incurred on a daily basis 
(depression, worry, medication side effects, etc.). In this study, social support was 
measured with the Medical Outcomes Study Social Support Survey (MOS-SSS) 
developed by Sherbourne and Stewart (1991). Backer (2000) concluded that greater 
dysfunction in psychosocial health was associated with low perceived availability of 
social support, frequent use of evasive coping, and more advanced stage of disease. Stage 
of disease was the only independent variable that was predictive of physical health 
dysfunction (Backer, 2000). Lastly, Backer’s (2000) study suggested that the four 
predictors examined (evasive coping, confrontational coping, perceived social support, 
and stage of disease) explained 31% of the variance in overall health dysfunction 
(psychosocial and physical health), 23% of the variance in physical health dysfunction, 
and 32% of the variance in psychosocial health dysfunction. The findings from this study 
provide implications for clinicians assessing overall health dysfunction in PD patients as 
well as those providing interventions to improve coping, availability of social support, 
and overall disease management (Backer, 2000).  
The majority of findings from studies examining the role of social support in PD 
patients are consistent with the previously established literature, which documents the 
variety of benefits that social support provides to the management of and coping with 
chronic disease.  
Relationships Between the Placebo Effect, Self-efficacy, and Social Support 
Placebo effect and self-efficacy. In response to the established literature that 
discusses the independent roles of the placebo effect and self-efficacy on health 
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outcomes, researchers have explored the mechanism of self-efficacy, and more generally 
the theory of expectancy, on the placebo effect. Bandura (1977, 1986, 1997) described 
two forms of expectancy, outcome expectations and self-efficacy expectations, and these 
forms of expectancy have been used to explain the placebo effect (Stewart-Williams & 
Podd, 2004). A comprehensive meta-analysis by Crow et al. (1999) examined the 
mechanisms of several forms of expectancies on the placebo effect within medical 
literature and synthesized its findings from this research. The authors’ review 
conceptualized the placebo effect within a framework of determinants, mechanisms, and 
outcomes. Specifically, Crow et al. considered four main determinants (patient, provider, 
patient-provider interaction, and treatment and setting) and four primary mechanisms 
(expectancy, anxiety reduction, classical conditioning, and social support) that were 
thought to act on health outcomes (health status, self-report, and objective measures). The 
meta-analysis considered expectancy to be the most “inclusive” mechanism and, 
therefore, focused on this domain (Crow et al., 1999). Crow et al.’s review of 93 primary 
articles on this topic confirmed that expectancy is a mechanism through which placebos 
operate and produce responses. Specifically, they found that expectancies were accessed 
in three different clinical areas: preparation for medical procedures, management of 
illness, and medical treatment (Crow et al., 1999). Primary forms of expectancy that have 
been reviewed in the literature are process expectancy, positive and negative outcome 
expectancy, interaction self-efficacy, and self-management self-efficacy. As previously 
mentioned, the literature generally confirmed that various forms of self-efficacy led to 
beneficial health outcomes in all three clinical areas. As such, Crow et al. (1999) argued 
for the implementation of clinical interventions that seek to enhance these outcome 
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expectancies and various forms of self-efficacy to ultimately increase the well-
documented benefits of the placebo response. A detailed review of each of the 93 primary 
articles will not be discussed here, but can be found in Crow et al. (1999).  
In another discussion of the placebo effect and the related cognitive psychological 
processes, Howard (2008) utilized expectancy theory as one model to explain the 
mechanisms and effects of the placebo effect. Specifically, Howard (2008) stated, “the 
expectations or beliefs patients have about treatment will influence how they respond to 
treatment” (p. 16). By this notion, patients who have positive expectations about a 
treatment may experience beneficial outcomes, even if they are administered a placebo or 
sham intervention (Howard, 2008). Similarly, patients who have negative expectations 
about the outcome of a treatment may experience deleterious effects. These adverse 
effects to a placebo have been termed nocebo effects (Barsky, Saintfort, Rogers, & 
Borus, 2002). Howard (2008) also discussed the effect treatment providers’ expectations 
can have on the beliefs patients hold about the treatment and therefore contribute to a 
positive placebo or negative nocebo effect. Other theories have been used to explain the 
placebo effect, such as classical conditioning, but will not be discussed here, as they are 
not within the scope of the present study (Stewart-Williams & Podd, 2004). 
Social support and the placebo effect. As mentioned in Crow et al.’s (1999) 
conceptual framework of the placebo effect, social support has been considered a 
mechanism through which the placebo effect functions. Researchers have investigated the 
role of social support on the placebo response in clinical trials (Kaptchuck et al., 2008; 
Miller, Colloca, & Kaptchuck, 2009). Most of this research has focused on the interaction 
and relationship between the patient and provider throughout the course of treatment. 
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Miller et al. (2009) explained that the placebo effect in the health care field relates 
specifically to the interaction between patients and clinicians, which leads to therapeutic 
outcomes such as symptom relief and coping with illness. One study by Kaptchuk et al. 
(2008) examined the role of the patient-clinician relationship in the placebo response in 
patients with irritable bowel syndrome who received a sham acupuncture treatment. The 
patients received the acupuncture from either a less supportive practitioner or a 
practitioner who demonstrated support and empathy. The results suggested that the 
placebo response was produced and it demonstrated therapeutic benefit by the sham 
acupuncture in this patient population (Kaptchuck et al., 2008). Furthermore, the study 
concluded that a larger percentage of participants who received the treatment by an 
acupuncturist who demonstrated support and empathy exhibited symptom relief than 
those who received the treatment from a less-supportive practitioner (Kaptchuck et al., 
2008). In other words, the placebo was enhanced and sustained when supplemented by 
additional supportive communication during the acupuncture (Kaptchuk et al., 2008).  
Miller et al. (2009) further discussed the various mechanisms through which the 
placebo response operates. Specifically, they discussed the placebo effect on a cultural 
level and explained that the placebo effect can be activated through the processes of 
social support (Miller et al., 2009). Similarly, Humphrey (2002) discussed the role of 
social influence and support on the placebo effect and explored the reasons why people 
often require “the intervention of others” or “outside permission” to take steps towards 
healing. Humphrey (2002) speculated that hope can activate internal healing processes 
and that this hope often comes from others. Miller et al. (2009) furthered this discussion 
and suggested “it is difficult to generate hope for relief by personal strategies,” but that 
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“it takes the intervention of an authoritative or protective figure to promote hope and 
expectation for relief, leading to the placebo effect” (p. 531). To summarize, social 
support has been found to be a mechanism through which the placebo effect operates in a 
variety of medical populations.  
Social support and self-efficacy. Given the empirical evidence that demonstrates 
the independent beneficial effects of social support and self-efficacy on health outcomes, 
it seems likely that these two constructs simultaneously play a role in health outcomes, 
specifically in patients with chronic diseases like PD. As previously discussed in the 
context of social support, Weiss (1974, as cited in Cutrona & Russell, 1987) described 
“reassurance of worth” by others as one category of his model of social provisions. 
Cutrona and Russell (1987) conferred that the presence of this provision, or the 
recognition of one’s competence and value by others, may enhance one’s sense of self-
efficacy and overall coping abilities. In other words, receiving this kind of positive 
feedback through supportive relationships can enhance one’s self-efficacy (Cutrona & 
Russell, 1987). Despite these conceptual links, few studies have examined the 
interrelationship of these two constructs, social support and self-efficacy, on health 
outcomes in chronic disease patients. One recent study by Kaşikçi and Alberto (2007) 
examined the role of familial support, perceived self-efficacy, and self-care behaviors in a 
sample of Turkish patients with chronic obstructive pulmonary disease. This study found 
positive relationships between self-care behaviors and familial support, self-care 




As previously discussed, self-efficacy has been found to predict self-management 
in PD patients (Chenoweth et al., 2008; Peteet, 2002 as cited in Chenoweth et al. 2008). 
Additional evidence for the relationship between social support, self-efficacy, and disease 
self-management was explored in studies conducted by Chenoweth et al. (2008) and 
Peteet (2002, as cited in Chenoweth et al., 2008). The results from these two studies 
(Chenoweth et al., 2008; Peteet, 2002, as cited in Chenoweth et al. 2008) suggested that 
high levels of social support lead to higher levels of self-efficacy, which ultimately 
predicted increased participation in self-management activities in PD patients. Therefore, 
it can be concluded that these three variables, social support, self-efficacy, and self-
management behaviors, are interrelated and thus should be assessed collectively in 
chronic disease populations such as PD. 
Summary 
Chapter Two included a detailed literature review of PD, treatments of PD, and 
the role of the placebo effect in medical interventions. This chapter also discussed the 
constructs of self-efficacy and social support, the role of these constructs in chronic 
disease populations such as PD, and how they relate to and influence the placebo effect. 
The current study was designed to investigate the predictive ability of self-efficacy and 
social support on physical functioning in PD patients who participated in the parent study 
and received fetal tissue implantation. The present study explored the influence of 
baseline levels of self-efficacy and social support on physical improvements at 12- and 
24-months post-fetal tissue implantations. This study also examined the influence of 
baseline levels of self-efficacy and social support on patients’ perceived treatment 12-
months after the initial surgery.  
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Chapter Three: Method 
Chapter Three describes the methodology followed in the present study. 
Information on the participants, procedures, measures, and data analyses is provided.  
Participants 
 Parent study. Forty patients with idiopathic Parkinson’s disease (PD) were 
recruited to participate in a double-blind surgical trial for the parent study conducted by 
Freed et al. (2001). Twenty patients were randomly assigned to the treatment group to 
receive fetal tissue implantation and 20 were assigned to the sham surgery group. Those 
patients in the sham surgery group were given the opportunity to receive the fetal tissue 
implantation after the blind was lifted 13-months following the initial surgery. The 
inclusion and exclusion criteria used for the parent study are described in detail below. 
More complete information describing the parent study can be found in Freed et al. 
(2001).   
 Inclusion criteria. There were several primary inclusion criteria for participants 
in the parent study (Freed et al., 2001). First, the patients needed to have been diagnosed 
with PD for at least seven years, presenting with at least two of the three major signs of 
PD (bradykinesia, rigidity, and tremor at rest), and demonstrating responsiveness to the 
L-dopa drug treatment. Specifically, patients needed to demonstrate continued 
responsiveness to L-dopa, but with reduced benefit. The patients were required to have 
previously tried other more conservative medical treatments for their PD. Patients were 
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required to be medically fit to undergo implantation surgery through the certification of 
their regular physician. Next, the patients needed to demonstrate the presence of an 
intractable problem that was not controlled by dopamine agonists, such as dyskinesias, 
“off” periods, or “freezing.”  The patients had to be willing to commit and actively 
participate in all aspects of the ongoing study and have the means to cover any expenses 
that were not initially covered by the parent study’s NIH grant. Age of the patients was 
required to be between 20 and 75 years old. As required by NIH, the parent study 
recruited a participant sample that was racially and ethnically representative of the 
prevalence rates of PD within each of the racial/ethnic groups. The prevalence rates used 
were current at the time of participant recruitment. Lastly, imaging results of a magnetic 
resonance imaging (MRI) scan of the brain in the last 18-months needed to indicate 
normal function and activity and a flurodopa PET scan needed to be compatible with 
idiopathic PD.  
 Exclusion criteria. The parent study also included a series of exclusion criteria 
(Freed et al., 2001). The patients in the parent study could not demonstrate any obvious 
depression, hallucinations, or cognitive impairments (as assessed by a 
neuropsychologist). The patients were also excluded if they had a history of previous 
brain surgery, injury, or exposure to toxins. The presence of any other severe medical 
diseases, such as diabetes mellitus, cardiopulmonary disease, or cerebrovascular disease, 
excluded patients from the study. Patients were also excluded from the study if they were 
taking any neuroleptic medications. Lastly, patients were not accepted into the parent 
study if they could not receive medical clearance from their regular physician to undergo 
the surgical procedure (Freed et al., 2001).   
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Quality of life study. The 40 patients in the parent study were invited to 
participate in the Quality of Life (QoL) study conducted by McRae et al. (2004); 30 
patients agreed to participate. The demographic information for these patients, as 
calculated by McRae et al. (2004), is presented in Table 1. This information was 
collected at true baseline and is grouped into the two conditions: treatment and sham 
surgery group.  
Table 1 
Demographic Information at True Baseline 
 
Demographic Variable 
Treatment Group  
(n = 12) 
Sham Surgery Group  
(n = 18) 
Total  
(n = 30) 
Gender         
             Female 










Age (M + SD) 59.9 + 7.9 56.3 + 10.4 57.8 + 9.5 
Education (M + SD) 16.6 + 2.8 16.3 + 2.2 16.4 + 2.4 
Duration of disease  
(M + SD) 
15.5 + 6.6 16.0 + 3.6 15.7 + 5.0 
Married/living with 
partner 
10 10 20 
Annual income > $40,000 9 10 19 
Currently employed 3 4 7 
Family history of PD 1 4 5 
Other chronic health 
problems 
5 2 7 
Currently smoke 0 1 1 
Ever smoke 2 7 9 
Ethnicity 
              Asian American 
African American 
            Latino/a 


















 All data for the present investigation were collected in the original QoL study 
conducted by McRae et al. (2004) from 1995 to 2000. No new data was collected for the 
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present study, but rather a secondary data analysis of the data collected by McRae et al. 
(2004) was conducted. The following is a description of the procedures followed by those 
researchers. 
Data were collected through written questionnaires that were sent to the patients 
one week after follow-up medical evaluations at the Irving Center for Clinical Research 
at Columbia-Presbyterian Medical Center (CPMC), now called the New York 
Presbyterian Hospital. The questionnaires assessed three domains of quality of life: 
Physical, Emotional, and Social functioning. Patients were provided with envelopes that 
included pre-paid postage and were asked to return their questionnaires to the 
researchers. For each completed and returned questionnaire, patients were paid $25. The 
response rate was 98%. The patients were instructed to respond to the questionnaires and 
not to have a third party complete the questionnaire on their behalf. The patients’ primary 
caregivers were also included in the study and were mailed separate questionnaires to 
complete, which evaluated the patients’ quality of life across the three domains. The data 
from the caregiver study were not analyzed in the present study.  
The patients were medically evaluated two times before the surgery and at 4-, 8-, 
12-, and 24-months after surgery. These evaluations lasted between three and four days to 
allow for an evaluation when the patients were both on and off medications. A 
neurologist and two research nurses provided medical care to the patients throughout the 
course of the study; these medical personnel were blind to the treatment group 






 Because of the uniqueness of this study and the lack of previous research with 
persons participating in double-blind clinical trials lasting more than one year, a broad 
range of measures was administered in order to assess changes over time. These measures 
were completed by the participants recruited in the original QoL study and were returned 
to the principal investigator through the mail. As described in the Procedures section, 
many of these measures were categorized into three main domains of QoL: Physical, 
Emotional, and Social functioning. The measures can be found in Appendices A through 
H. 
 Physical functioning. The patients’ level of Physical functioning was assessed 
with several measures that are uniformly recognized as assessment tools for patients with 
PD: the patient version of the Unified Parkinson’s Disease Rating Scale (UPDRS); 
(Montgomery, Lieberman, Sing, & Fries, 1994), the Hoehn and Yahr Stage of Disease 
scale (Hoehn & Yahr, 1967), and the Schwab and England Activities of Daily Living 
scale (Schwab & England, 1969). In addition, a single item called the “Free or 
Restricted” item was used. 
 Unified Parkinson’s Disease Rating Scale. Patients’ self-reported level of 
physical functioning was assessed through the patient version of the Unified Parkinson’s 
Disease Rating Scale (UPDRS); (Montgomery, Lieberman, Sing, & Fries, 1994). This 
measure was adapted from the standard neurologist version of this measure (Fahn, Elton, 
& Members of the UPDRS Development Committee, 1987). The patient version of the 
UPDRS measures patients’ perception of their physical functioning and overall physical 
problems related to PD. This measure consists of four primary subscales: Activities of 
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Daily Living (ADLs) at their “best”, ADLs at their “worst”, Severity of Symptoms at 
their “best”, and Severity of Symptoms at their “worst.” These qualitative descriptors of 
“best” and “worst” correspond to the patients’ physical functioning “at their best” and 
their physical functioning “at their worst.”  
The two ADLs subscales include eight items that are scored on a 5-point Likert 
scale with the following descriptors: 1 (Normal), 2 (Adequate), 3 (Limited), 4 (Need 
help), and 5 (Unable to do). Each of the scales is scored separately and patients can score 
a minimum of eight points and maximum of 40 points, with lower scores indicating better 
physical functioning. The eight activities of daily living that are rated on these subscales 
are walking, dressing, cutting food, performing personal hygiene tasks, getting up from a 
chair, turning in bed, writing, and talking. 
The two Severity of Symptoms subscales rate five problem areas that are scored 
on a 5-point Likert scale with the following descriptors: 1 (Normal), 2 (Mild), 3 
(Moderate), 4 (Severe), and 5 (Very Severe). Each of these scales is scored separately and 
the total scores range from five to 25, with lower scores indicating better physical 
functioning. The five problems rated include tremor, swallowing, salivation, “freezing” 
when walking, and falling. As discussed in the parent and the QoL study, previous 
research has demonstrated that the scores “off” medications are a more accurate 
assessment of the patients’ status, therefore only the “worst” scores were included in the 
composite variable in the data analysis (Freed et al., 2001; McRae et al., 2004).  
The estimate of reliability (Cronbach’s alpha) for the patient version of the 
UPDRS in this sample ranged from .65 to .90 (McRae, et al., 2004). This estimate was re-
computed in the preliminary analyses of the present study. The original patient version of 
 
60 
the UPDRS has demonstrated acceptable construct validity when compared to other 
widely used measures assessing physical functioning in patients with PD according to 
Ramaker, Marinus, Stiggelbout, and van Hilten (2002).  
 Hoehn and Yahr Stage of Parkinson’s disease scale. The patients’ stage of 
disease was assessed with the Hoehn and Yahr Stage of Disease scale (1967), which is a 
standard rating scale for PD. The patients were asked to rate their stage of disease on a 
scale ranging from zero to five; 0 (no signs of the disease), 1 (evidence of the disease on 
one side of the body), 2 (evidence of the disease on both sides of the body; without 
impairment of balance), 3 (mild to moderate bilateral disease; some postural instability; 
physically independent), 4 (severe disability; still able to walk or stand unassisted) and 5 
(wheelchair bound or bedridden unless aided). The patients provided ratings at a baseline 
assessment before the surgery and at each of the follow-up assessments (four-, eight-, 12-
, 24-, and 36-months). The version of the scale utilized in the QoL study was previously 
adapted for patient use and was found to correlate with ratings by neurologists (McRae et 
al., 2002). The estimate of reliability of this measure was assessed within the sample 
during the preliminary data analyses. Information on the construct validity of this scale 
was not available. Because this measure was used in the parent study and has been 
consistently used in previous studies with this data, it was used in the present study. 
Schwab and England Activities of Daily Living scale. Schwab and England 
(1967) developed this scale to specifically assess the level of physical functioning of PD 
patients related to activities of daily living. This scale has been widely used in research 
studies with this patient population (Goetz, et al., 1989). The scale asks the patients to 
indicate one response “that best describes your present activity level.” The responses are 
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graded in 10% increments, from 0% to 100%. Each of these ratings corresponds to a brief 
qualitative descriptor. For example, 0% corresponds to the following statement, 
“Vegetative functions such as swallowing, bladder and bowel functions are not 
functioning. Bed-ridden.” A 50% rating is accompanied with the following description, 
“More dependent. Help with half of chores, slower, etc. Difficulty with everything.” 
Lastly, a rating of 100% indicated “Completely independent. Able to do all chores 
without slowness, difficulty or impairment. Essentially normal. Unaware of any 
difficulty.” Patients rated themselves on this scale at baseline and each of the follow-up 
assessments (four-, eight-, 12-, 24-, and 36-months) in the original QoL study. The 
estimate of reliability of this measure was assessed within the sample during the 
preliminary data analyses. This measure has demonstrated moderate to substantial 
validity (Ramaker et al., 2002). 
 Free and Restricted Scale. This scale consists of a single, global item that was 
used to assess how free or restricted patients feel “in doing what [they] want to do.” The 
patients in this study rated their functioning using a 7-point rating scale ranging from 1 (I 
still do everything I want to do) to 7 (I can no longer do the things I want to do). Lower 
scores indicated better physical functioning as it relates to quality of life activities. The 
estimate of reliability of this measure was assessed within the sample during the 
preliminary data analyses. Information on the construct validity of this single-item scale 
was not available. Because this measure was used in the parent study and has been 
consistently used in previous studies with this data, it was used in the present study.  
 Emotional functioning. In the original QoL study, the participants’ level of 
Emotional functioning was assessed with multiple measures that examined mood, stress, 
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and the intrusiveness of the patients’ disease. The measures used to assess these aspects 
of Emotional functioning are not within the scope of the present study and therefore will 
not be discussed here (please see McRae et al. [2004] for additional information on these 
scales).  
Self-efficacy. Self-efficacy is a construct that was assessed in the original QoL 
study by McRae et al. (2004), but has not been investigated in previous analyses with this 
data. Therefore, self-efficacy was the primary focus of the present study. 
Self-efficacy Scale. A measure of self-efficacy was adapted from Lorig et al.’s 
(1993) previous work with self-efficacy and was used by McRae et al. (2004) for the 
original QoL study to assess the patients’ level of self-efficacy related to the management 
of their disease and attending circumstances. Measurement of self-efficacy occurred at 
baseline and each follow-up assessment. The scope of this assessment was specific to 
patients’ beliefs about managing various aspects of their chronic disease, PD. This 
measure was adapted from the work of Lorig et al. (1993) who first investigated self-
efficacy among persons with arthritis. Lorig and colleagues have developed several self-
management programs for a variety of chronic disease patient populations including 
those with diabetes, cancer, and chronic obstructive pulmonary disease. The self-efficacy 
scale used in the QoL study consisted of seven items assessing self-efficacy on a 7-point 
Likert scale. Each item was prefaced with the phrase, “How certain are you that you 
can…” Examples of items on the self-efficacy scale include, “do something to help 
yourself feel better if you are feeling blue?” and “manage your situation so that you can 
do the things that you enjoy doing?” The scale ranged from 1 (very uncertain) to 7 (very 
certain) indicating the patients’ level of certainty that they could perform the task 
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described in the item. Higher scores correspond with higher levels of self-efficacy and 
lower scores correspond with lower levels of self-efficacy. The estimate of reliability of 
this measure was assessed within the sample during the preliminary data analyses. 
Similar measures developed by Lorig et al. (1993) in the chronic disease population have 
demonstrated acceptable levels of construct validity.  
 Social functioning. The participants’ level of Social functioning was primarily 
assessed with one measure of perceived social support. The measure used in the original 
QoL study was the Social Provisions Scale (Cutrona & Russell, 1987).  
 Social Provisions Scale. The Social Provisions Scale was developed by Cutrona 
and Russell (1987) to measure perceived social support. The scale is 24-items that are 
measured on a 4-point Likert scale. The scale ranges from 1 (strongly disagree) to 4 
(strongly agree). Total scores on this measure range from 24 to 96, with lower scores 
corresponding to lower levels of perceived social support. The reliability estimate in the 
original QoL study at baseline was .91 (Cronbach’s alpha; McRae et al., 2004). This 
estimate was re-analyzed in the preliminary analyses of the present study. Construct 
validity for this instrument has been established (Russell et al., 1984).  
 Perceived treatment. 12-months after receiving the initial surgery, those patients 
who participated in the QoL study were asked to report which treatment, actual neural 
implantation or sham surgery, they believed they received (McRae et al., 2004). This 
discrete response of perceived treatment, neural tissue implant or sham surgery, served as 






 A secondary data analysis was conducted with the data collected from the original 
QoL study. The analyses had a preliminary analysis stage as well as a primary analysis 
stage.  
Preliminary data analyses were conducted in order to obtain demographic 
information as well as descriptive statistics. Due to the use of multiple measures of 
physical functioning, preliminary analyses created a composite variable within the 
physical functioning domain, which was used in the primary data analyses. The creation 
of this composite variable served to decrease the number of dependent variables used in 
the primary analyses and improve the strength of the statistical analyses. Reliability 
estimates for each of the measures was re-examined prior to the primary analyses. The 
primary data analyses were conducted in order to answer the following research 
questions:  
1. Are self-efficacy and perceived social support at adjusted baseline correlated 
with physical functioning at 12- and 24-months post-fetal tissue implantation? 
2a. Do self-efficacy and perceived social support at adjusted baseline predict 
physical functioning of PD patients 12-months following fetal tissue implantation? Does 
the interaction term of social support x self-efficacy at adjusted baseline predict physical 
functioning of PD patients 12-months following fetal tissue implantation? 
2b. Do self-efficacy and perceived social support at adjusted baseline predict 
physical functioning 24-months following fetal tissue implantation? Does the interaction 
term of social support x self-efficacy at adjusted baseline predict physical functioning of 
PD patients 24-months following fetal tissue implantation? 
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3. Do self-efficacy and perceived social support at true baseline predict perceived 
treatment at 12-months after the initial surgery? 
Because patients who originally received the sham surgery were given the 
opportunity to have the actual fetal tissue implantation once the blind was lifted 13-
months after the first surgery, this study examined the patient data at 12- and 24-months 
after the actual fetal tissue implantation (or 24- and 36-months after the initial surgery for 
those in the sham surgery group).  
The first research question was answered through Pearson’s product moment 
correlation (r). This analysis tested for a linear relationship between self-efficacy and 
perceived social support at adjusted baseline and physical functioning at 12- and 24-
months post-fetal tissue implantation. For the purposes of this analysis, both scales of 
social support and self-efficacy were considered continuous measures and it was assumed 
that there was a meaningful difference between each of the values on the rating scales. 
The following assumptions of Pearson’s product moment correlation were examined: 
normality and linearity. However, due to the small sample size and unique exploratory 
nature of the study, violations of these assumptions did not prevent further analyses. 
The second set of research questions (2a and 2b) was answered through 
hierarchical linear regression analyses, as this is the method used to predict the scores on 
a dependent variable based on values of multiple independent variables. In this case, the 
analyses tested the ability of two primary independent predictors, self-efficacy and 
perceived social support at adjusted baseline, to predict the dependent variables, physical 
functioning at 12- and 24-months post-fetal tissue implantation. For the purposes of these 
analyses, both scales of social support and self-efficacy were considered continuous 
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measures and it was assumed that there is a meaningful difference between each of the 
values on the rating scales. Additionally, the analyses of physical functioning at 12- and 
24-months controlled for patients’ length of PD diagnosis and level of physical 
functioning at adjusted baseline. In other words, length of PD diagnosis and physical 
functioning at baseline were considered step one in the regression analyses. The first 
independent variable of interest, perceived social support at adjusted baseline, was 
entered independently into the regression analyses and was considered step two. Next, the 
second independent variable of interest, self-efficacy at adjusted baseline, was added to 
the regression analyses as step three. It was determined to enter perceived social support 
into the regression model before self-efficacy based on previous work with this data set, 
which suggested that social support was a significant predictor of physical functioning in 
this sample. The present study was principally interested to reveal the unique contribution 
of self-efficacy to the regression model as well as the interaction between the two 
constructs, social support and self-efficacy. Finally, a second analysis examined the 
ability of the interaction between perceived social support and self-efficacy at adjusted 
baseline to predict physical functioning at 12- and 24-months post-fetal tissue 
implantation.  
Data were screened for outliers on the independent and dependent variables using 
Mahalanobis distance. The following assumptions of regression were examined: 
normality of the predictors, homoscedasticity, and linearity. Independence between 
independent variables was tested. The data were analyzed for multicollinearity and 
singularity. However, violations of these assumptions did not prevent further analyses, 
due to the small and unique sample as well as the exploratory nature of the study.   
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The third research question was answered using logistic regression. The patients’ 
perception of treatment at 12-months after the initial surgery was a discrete variable, 
either neural tissue implant or sham surgery group, and was predicted by two continuous 
independent variables, self-efficacy and perceived social support at true baseline. This 
analysis controlled for patients’ length of PD diagnosis and physical functioning at true 
baseline, which was considered step one. The two variables of interest, self-efficacy and 
perceived social support at true baseline, were considered step two. Similar to the first set 
of primary analyses, data were screened for outliers on the independent variables using 
Mahalanobis distance. The following assumptions of regression were examined: 
normality of the predictors, and linearity. Independence between independent variables 
was tested. The data were analyzed for an absence of multicollinearity and singularity. 
Again, violations of these assumptions did not prevent further analyses, due to the small 
and unique sample size as well as the exploratory nature of the study.   
Summary 
 Chapter Three described the methodology that was used in this study. A 
description of the participants, procedures, measures, and data analyses was provided. 
The preliminary and primary data analyses that were used to answer the three main 
research questions were discussed.  
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Chapter Four: Results 
Overview 
Chapter Four presents the results of the statistical analyses directed to the research 
questions of the present study. A description of the preliminary analyses is provided 
along with the findings of the primary analyses. All statistical analyses were performed 
using the Statistical Package for the Social Sciences 21 for Mac (SPSS 21). The statistical 
analyses used two-tailed tests of significance with the alpha level set at p < .1 because of 
the experimental nature of the study and the small sample size.  
As previously described, the participants were assigned to one of two treatment 
groups during the parent study (Freed et al., 2001). Those in the original implant group 
received fetal tissue implantation during the first surgery (n = 20). Of these 20 
participants, 12 participated in the QoL study. The second treatment group received a 
sham surgery initially (n = 20) and then had the option of receiving the fetal tissue 
implantation after the blind was lifted at 13-months. Of these 20 participants, 18 
participated in the QoL study.  
The first and second research questions posed in the present study required the 
comparison of QoL variables at baseline, 12-, and 24-months after fetal tissue 
implantation. Due to the one-year double blind period and the two treatment groups 
having the implantation at least one year apart, adjustments were made in terms of data 
entry in order to align the temporal course of the surgeries. Therefore, true baseline 
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measurements for the sham group collected before the initial sham surgery were 
substituted with measurements taken 12-months after the initial surgery. These 12-month 
scores were the most representative of the sham participants immediately before 
receiving the actual implantation during the second surgery. If the true baseline 
measurements taken before the initial surgery were used, it would represent the state of 
participants more than one year prior to receiving the actual tissue implantation. This data 
shift was performed with all variables for the sham group in order to temporally equate 
their measurements with the implant group relative to the time the fetal tissue 
implantation surgery was performed. All of the primary statistical analyses conducted to 
answer Research Questions 1, 2a, and 2b were performed using this shifted data. It is 
noted throughout the preliminary analyses and the primary analyses for Research 
Question 3 when the true baseline measurements (i.e., before the initial surgery) were 
used; otherwise it should be assumed that all analyses were done with the shifted data.  
Preliminary Analyses 
 Demographic information. As previously discussed in Chapter Three, 
demographic information had previously been collected on the 30 participants who 
participated in the QoL study (McRae et al., 2004). Chapter Three presented a summary 
of the demographic information calculated by McRae et al. (2004). The present study re-
calculated these statistics. The re-calculated statistics were identical to those calculated 
by McRae et al. (2004) and are presented in Table 2. This information was collected 











Treatment Group  
(n = 12) 
Sham Surgery Group  
(n = 18) 
Total  
(n = 30) 
Gender: Female 







Age (M + SD) 59.9 + 7.9 56.3 + 10.4 57.8 + 9.5 
Education (M + SD) 16.6 + 2.8 16.3 + 2.2 16.4 + 2.4 
Duration of disease (M + SD) 15.5 + 6.6 16.0 + 3.6 15.7 + 5.0 
Married/living with partner 10 10 20 
Annual income > $40,000 9 10 19 
Currently employed 3 4 7 
Family history of PD 1 4 5 
Other chronic health problems 5 2 7 
Currently smoke 0 1 1 
Ever smoke 2 7 9 
Ethnicity: Asian American 
African American 
                Latino/a 














Descriptive statistics of QoL measures. Descriptive statistics for the QoL 
measures used in the present study were computed. The means, standard deviations, 
ranges, sample sizes, skewness values, and kurtosis values for each of the physical 
functioning measures at adjusted baseline, 12-months post-fetal tissue implantation, and 
24-months post-fetal tissue implantation are presented. The descriptive statistics for the 
physical functioning composite variable are presented at true baseline, adjusted baseline, 
12-months post-fetal tissue implantation, and 24-months post fetal tissue implantation, as 
all four of these time points were used in the primary statistical analyses. Finally, the 
descriptive statistics for the social support and self-efficacy measures are presented at 
true baseline and adjusted baseline only, as these are the only time points that were 





Descriptive Statistics of QoL Measures  
 
 N M SD Range Skewness Kurtosis 
Physical Functioning  
(Lower Scores = Better Functioning) 
  
UPDRS: Activities of 
Daily Living (at worst) 
      
Adjusted Baseline 29 28.69 6.27 13.0 – 40.0 -.32 .22 
12-months post-
implantation 
23 24.96 6.93 12.0 – 38.0 .07 -.48 
24-months post-
implantation 
20 21.75 6.03 11.0 – 33.0 .11 -.74 
UPRDRS: Severity of 
Symptoms (at worst) 
      
Adjusted Baseline 30 13.23 2.81 7.0 – 19.0 .08 -.15 
12-months post-
implantation 
22 12.68 3.59 6.0 – 18.0 -.17 -.93 
24-months post-
implantation 
20 11.80 4.16 6.0 – 22.0 .72 .30 
Free or Restricted Scale       
Adjusted Baseline 30 4.73 1.48 2.0 – 7.0 -.66 -.50 
12-months post-
implantation  
22 4.09 1.69 2.0 – 7.0 .17 -1.49 
24-months post-
implantation  
20 3.45 1.57 1.0 – 6.0 .33 -.82 
Physical Functioning 
Composite Score (z-scores) 
      
True Baseline 29 .00 2.40 -6.56 – 4.21 -.42 .54 
Adjusted Baseline 29 .19 2.30 -5.35 – 4.95 -.16 .03 
12-months post-
implantation 
28 .09 2.51 -4.86 – 4.95 .001 -.65 
24-months post-
implantation 
20 .17 2.53 -5.41 – 5.48 -.15 .57 
Social Functioning  
(Higher Scores = Better Functioning) 
  
Social Provisions Scale       
True Baseline 27 80.41 9.17 58.0 – 96.0 -.16 -.04 
Adjusted Baseline 29 79.72 9.98 67.0 – 96.0 .17 -1.65 
Self-Efficacy  
(Higher Scores = Better Functioning) 
  
Self-Efficacy Scale       
True Baseline 29 37.86 7.74 19.0 – 49.0 -.53 -.007 




Reliability of variables used to answer primary research questions. The 
reliability estimates, specifically Cronbach’s α, were calculated for each of the scales 
used to answer the research questions in this study. These estimates were calculated as 
part of the preliminary analyses in order to examine the internal consistency of the 
measures. The reliability estimates at true baseline for these scales are presented in Table 
4. The Free and Restricted variable was a single-item scale and therefore a reliability 
estimate was not calculated. Although the UPDRS Severity of Symptoms at Worst scale 
was not in the acceptable range, it was used in the primary analyses because it has been 
consistently used in previous work with these data. Item analysis revealed that Item 1 of 
this scale, “Tremor,” was negatively related to the other items in the scale. The item 
analyses suggested that if Item 1 “Tremor” and Item 3 “Salivation” were removed from 
the scale, the reliability estimate would be in the acceptable range at true baseline. 
Further analyses of this scale demonstrated that the reliability estimate increased at 12- 
and 24-month follow-up (12-month: Cronbach’s α = .64, 24-month: Cronbach’s α = .88). 
Furthermore, tremor and salivation are cardinal symptoms of PD and therefore it was 
important that these symptoms were accounted for in the measurement of physical 
functioning. Therefore, it was decided to include all five items of the UPDRS Severity of 
Symptoms at Worst Scale in the primary analyses. All other scales had reliability 
estimates in the acceptable range of .7 (Nunnally, 1978).  
Correlations of QoL variables. Pearson’s (r) correlations were calculated in 
order to examine the linear relationships between the QoL variables. The relationships 
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between the physical functioning variables at true baseline were examined as well as the 
relationship between the measures of social support and self-efficacy.  
Table 4 
 
Reliability Estimates of QoL Measures at True Baseline 
 
QoL Measures at True Baseline Cronbach’s  α 
Physical Functioning  
UPDRS: Activities of Daily Living at Worst .90 
UPDRS: Severity of Symptoms at Worst .09 
Social Functioning  
Social Provisions Scale .91 
Self-Efficacy  
Self-Efficacy Scale .91 
 
Assumptions of Pearson’s product moment correlation were met. Specifically, no 
univariate outliers were identified and the variables of interest, Activities of Daily Living 
at Worst, Severity of Symptoms at Worst, and Free and Restricted, were considered to be 
continuous variables.  
The linear relationships between the physical functioning variables at true 
baseline were investigated using Pearson’s product moment correlation. As displayed in 
Table 5, strong, positive linear relationships existed between the Free and Restricted 
Scale and the Activities of Daily Living at Worst Scale (r = .50, p < .01) as well as the 
Severity of Symptoms at Worst Scale and the Activities of Daily Living at Worst Scale (r 
= .59, p < .01). A moderate, positive linear relationship existed between the Free and 
Restricted Scale and the Severity of Symptoms at Worst Scale (r = .296, p = .12). The 
strength and direction of these relationships provided justification to combine them and 
create a composite variable for the physical functioning domain.  
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The administration of the Schwab and England Activities of Daily Living Scale 
(Schwab & England, 1967) changed during the course of the QoL study and therefore a 
consistent score for this measure was not available at each data collection period. For this 
reason, the Schwab and England scale was not included in the physical functioning 
composite variable despite the strong correlations with other measures of physical 
functioning (see Table 5). This was consistent with previous work done with this data set.  
Table 5 
 
Pearson Correlation Coefficients for Physical Functioning QoL Variables at True 
Baseline 
 
 Free or 
Restricted 
Activities of 
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Data for the Hoehn and Yahr Stage of Parkinson’s Disease scale (Hoehn & Yahr, 
1967) were not available at true baseline and therefore were not examined in the 
correlation analyses and were not included in the physical functioning composite 
variable. 
Pearson’s (r) correlation analyses were conducted in order to examine the linear 
relationships between the measures of social support and self-efficacy at true baseline. 
Assumptions of Pearson’s product moment correlation were met. Specifically, no 
univariate outliers were identified and the variables of interest, social support and self-
efficacy, were considered to be continuous variables. As displayed in Table 6, a strong, 
positive linear relationship existed between perceived social support and self-efficacy (r 
= .42, p < .05).  
Table 6 
 
Pearson Correlation Coefficients for Self-efficacy and Social Support at True Baseline 
 Social Provisions Scale Self-efficacy Scale 


























Note. * p < .1  ** p < .05. 
Creation of the composite variable. As presented in Table 5, there were strong 
correlations between the following measures of physical functioning: Free and Restricted 
Scale, Activities of Daily Living at Worst Scale, and Severity of Symptoms at Worst 
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Scale. Therefore these measures were combined to create one composite variable to 
represent the physical functioning domain. This was done for each of the following time 
points: true baseline, adjusted baseline, 12-months post-fetal implantation, and 24-months 
post-fetal implantation. Please see the section entitled “Overview” in this chapter for a 
description of how and why the data were shifted to adjust for the different surgery dates 
within the treatment groups. Scores for each of the measures were standardized at each 
period based on the mean and standard deviation of that measure at that time period. The 
standard scores for each measure were then combined to create a total z-score that 
comprised the composite variable. A reliability estimate, specifically Cronbach’s α, was 
then calculated for the physical functioning composite variable at the adjusted baseline 
(Cronbach’s α = .65). While this reliability estimate is not above the acceptable range of 
.7 (Nunnally, 1978), it was decided to use the composite variable in the primary analyses 
because it approached the acceptable range and has been used in previous work with 
these data.  
Primary Analyses 
 The previous section presented demographic information, descriptive statistics of 
the QoL variables, reliability estimates, correlations of the QoL variables, and a 
description of how the composite physical functioning variable was created. This section 
presents the results of the primary analyses that were conducted in order to answer the 
research questions of the study. All statistical analyses used two-tailed tests of 
significance and the alpha level was set at p < .1 because of the experimental nature of 
the study and the small sample size.  
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Research question 1. Are self-efficacy and perceived social support at adjusted 
baseline correlated with physical functioning at 12- and 24-months post-fetal tissue 
implantation?  
As previously discussed, all data were adjusted to account for the two treatment 
groups and the fetal tissue implantation surgeries that occurred one year apart. Therefore, 
“adjusted baseline” measures of self-efficacy and social support represented 
measurements 12-months before participants received the actual implantation. Likewise, 
the physical functioning scores at 12- and 24-months represented measurements recorded 
12- and 24-months after the real implantation occurred, not from the date of the initial 
surgery, as the sham group did not receive the actual fetal tissue implantation until the 
second surgery.  
Assumptions of Pearson’s product moment correlation were met. Specifically, no 
univariate outliers were identified and the variables of interest, self-efficacy at adjusted 
baseline, social support at adjusted baseline, and physical functioning at 12- and 24-
month follow-up, were considered to be continuous variables.  
The linear relationships between self-efficacy and perceived social support at 
adjusted baseline and the physical functioning composite variable at 12- and 24-months 
post-fetal tissue implantation were investigated using Pearson’s product moment 
correlation. As displayed in Table 7, a strong, positive linear relationship existed between 
self-efficacy and perceived social support at adjusted baseline (r = .43, p < .05). A strong, 
negative linear relationship was observed between self-efficacy at adjusted baseline and 
physical functioning at 12-months post-fetal tissue implantation (r = -.43, p < .05). A 
strong, positive linear relationship existed between physical functioning at 12- and 24-
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months post-fetal tissue implantation (r = .54, p < .05). Social support did not 
demonstrate strong, linear relationships with the physical functioning composites at 12- 
or 24-months post-fetal tissue implantation (see Table 7).  
Table 7 
 
Pearson Correlation Coefficients for Self-efficacy and Social Support at Adjusted 
Baseline and Physical Functioning Composite at 12- and 24-months Post-fetal Tissue 
Implantation 
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Note. * p < .1  ** p < .05. 
 
79 
Research question 2a. Do self-efficacy and perceived social support at adjusted 
baseline predict physical functioning of PD patients 12-months following fetal tissue 
implantation? 
A hierarchical multiple regression analysis was conducted in order to answer 
Research Question 2a. This analysis controlled for the patients’ length of PD diagnosis 
and level of physical functioning at adjusted baseline. In other words, these control 
variables comprised step one of the regression analysis. Perceived social support at 
adjusted baseline was entered into the analysis as step two. Self-efficacy at adjusted 
baseline was entered into the model as step three. It was determined to enter perceived 
social support into the regression model before self-efficacy based on previous work with 
this data set, which suggested that social support was a significant predictor of physical 
functioning in this sample. The present study was principally interested to examine the 
unique contribution of self-efficacy to the regression model as well as the interaction 
between the two constructs, social support and self-efficacy.  
All assumptions of multiple regression were tested and met. Specifically, a review 
of the histograms and skewness and kurtosis values determined that the independent and 
dependent variables were normally distributed. The control variable, patients’ length of 
PD diagnosis, was slightly positively skewed, but was still included in the analyses as 
multiple regression is robust to assumption violations such as this. The assumption of 
homoscedasticity was met, as the distribution of the standardized residuals along the fit 
line appeared to be constant. Scatterplots examining the relationship between the 
independent and the dependent variables appeared linear, and therefore this assumption 
of multiple regression was met. The data were screened and no multivariate outliers were 
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identified. Finally, the variance inflation factor demonstrated that the independent 
variables were not multicollinear.  
The regression model, with adjusted baseline levels of self-efficacy and social 
support as predictors, was found to be statistically significant, R2(4,23) = .63,  p < .001. 
Therefore, 63.0% of the variance in the physical functioning composite scores 12-months 
post-fetal tissue implantation was explained by self-efficacy and social support levels at 
adjusted baseline when the patients’ length of PD diagnosis and physical functioning 
scores at adjusted baseline were controlled. The regression model was not significantly 
improved with the addition of step two, or social support at adjusted baseline. It was not 
until step three was added, or self-efficacy at adjusted baseline, that the regression model 
was significantly improved. See Table 8 below for details. Of the two predictors, self-
efficacy was significant and contributed more to the prediction of physical functioning at 
12-months (β = -.30, p < .1) than social support (β = .14, p = .35). Specifically, the model 
and the slopes of the predictors suggested that as self-efficacy scores at baseline 
increased, physical functioning scores 12-months post-fetal tissue implantation 
decreased, or in other words, improved. As total scores on the social support scale at 
baseline increased, the physical functioning composite scores at 12-month follow-up also 
increased, or in other words, worsened (lower scores on the physical functioning 
composite suggested better functioning).  
The control variables, patients’ length of PD diagnosis (β = .24, p < .1) and 
physical functioning at adjusted baseline (β = .64, p < .001), were also found to be 




A second hierarchical multiple regression analysis was conducted in order to 
further explore Research Question 2a: Does the interaction term of self-efficacy x 
perceived social support at adjusted baseline predict physical functioning of PD patients 
12-months following fetal tissue implantation? This analysis controlled for the patients’ 
length of PD diagnosis and level of physical functioning at adjusted baseline. In other 
words, these control variables comprised step one of the regression analysis. An 
interaction term was calculated for perceived social support and self-efficacy at adjusted 
baseline. The interaction term was calculated by multiplying the centered values (score – 
mean) of the social support and self-efficacy variables at adjusted baseline. The 
interaction term and the centered social support and self-efficacy variables were entered 
into the analysis as step two.  
Table 8 
Hierarchical Multiple Regression Analyses Predicting Physical Functioning 12-months 
Post-Fetal Tissue Implantation From Social Support and Self-efficacy 
 
 Physical Functioning 12-months 
Post-Fetal Tissue Implantation 
Predictor R2 ΔR2 Adjusted 
R2 
 β 
Step 1: Control Variables .56*** .56*** .53***  
PD Duration    .22 
Baseline Physical Functioning    .71*** 
Step 2 .56*** .001 .51***  
PD Duration    .22 
Baseline Physical Functioning    .71*** 
Social Support    .02 
Step 3 .63*** .065* .56***  
PD Duration    .24* 
Baseline Physical Functioning    .64**** 
Social Support    .14 
Self-efficacy    -.30* 
Note. * p < .1  ** p < .05  *** p < .01 **** p < .001. 
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The regression model, with centered social support, centered self-efficacy, and the 
centered interaction term as predictors, was statistically significant, R2(5,22) = .63,  p < 
.001. However, this model was not a significant improvement from the regression model 
comprised of only the control variables. See Table 9 below for details. The interaction 
term was not found to be a statistically significant predictor of physical functioning 12-
months post-fetal tissue implantation (β = -.07, p = .63).  
As previously described, the control variable physical functioning at adjusted 
baseline (β = .66, p < .001) was a statistically significant predictor of physical functioning 
12-months post-fetal tissue implantation. The control variable, patients’ length of PD 
diagnosis (β= .23, p =.10), was not statistically significant (see Table 9). 
Table 9 
 
Hierarchical Multiple Regression Analyses Predicting Physical Functioning 12-months 
Post-Fetal Tissue Implantation From Interaction Term Social Support x Self-efficacy 
 
 Physical Functioning 12-months 
Post-Fetal Tissue Implantation 
Predictor R2 ΔR2 Adjusted 
R2 
 β 
Step 1: Control Variables .56**** .56**** .53****  
PD Duration    .22 
Baseline Physical Functioning    .71**** 
Step 2 .63**** .07 .55****  
PD Duration    .23 
Baseline Physical Functioning    .66**** 
Centered Social Support    .14 
Centered Self-efficacy    -.28* 
Centered Interaction Term 
Social Support x Self-efficacy 
   -.07 
Note. * p < .1  ** p < .05  *** p < .01 **** p < .001. 
Research question 2b. Do self-efficacy and perceived social support at adjusted 
baseline predict physical functioning 24-months following fetal tissue implantation? 
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A hierarchical multiple regression analysis was run in order to answer Research 
Question 2b. This analysis controlled for the patients’ length of PD diagnosis and level of 
physical functioning at adjusted baseline; these control variables comprised step one of 
the regression analysis. Similar to Research Question 2a, perceived social support at 
adjusted baseline was entered into the analysis as step two. Self-efficacy at adjusted 
baseline was entered into the model as step three. Again, it was determined to enter 
perceived social support into the regression model before self-efficacy based on previous 
work with this data set, which suggested that social support was a significant predictor of 
physical functioning in this sample. The present study was principally interested to 
examine the unique contribution of self-efficacy to the regression model as well as the 
interaction between the two constructs, social support and self-efficacy.  
All assumptions of multiple regression were tested and met. Specifically, a review 
of the histograms and skewness and kurtosis values determined that the independent and 
dependent variables were normally distributed. The control variable, patients’ length of 
PD diagnosis, was slightly positively skewed, but was still included in the analyses as 
multiple regression is robust to assumption violations such as this. The assumption of 
homoscedasticity was met, as the distribution of the standardized residuals along the fit 
line appeared to be constant. Scatterplots examining the relationship between the 
independent and the dependent variables appeared linear, and therefore this assumption 
of multiple regression was met. The data were screened and no multivariate outliers were 
identified. Finally, the variance inflation factor demonstrated that the independent 
variables were not multicollinear.  
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The regression model, with baseline levels of self-efficacy and social support as 
predictors, was not statistically significant, R2(4,15) = .36,  p = .13, although the model 
comprised of the control variables, length of PD diagnosis and physical functioning at 
adjusted baseline, was significant (see Table 10). The control variable, physical 
functioning at adjusted baseline (β = .57, p < .05) was found to be a statistically 
significant predictor of physical functioning 24-months post-fetal tissue implantation; 
length of PD diagnosis (β = -.15, p = .48) was not statistically significant. See Table 10 
for details.  
Table 10 
Hierarchical Multiple Regression Analyses Predicting Physical Functioning 24-months 
Post-Fetal Tissue Implantation From Social Support and Self-efficacy 
 
 Physical Functioning 24-months 
Post-Fetal Tissue Implantation 
Predictor R2 ΔR2 Adjusted 
R2 
 β 
Step 1: Control Variables .28* .28* .19*  
PD Duration    -.11 
Baseline Physical Functioning    .51** 
Step 2 .34* .07 .22*  
PD Duration    -.16 
Baseline Physical Functioning    .60** 
Social Support    .28 
Step 3 .36 .01 .19  
PD Duration    -.15 
Baseline Physical Functioning    .57** 
Social Support    .33 
Self-efficacy    -.13 
Note. * p < .1  ** p < .05. 
A second hierarchical multiple regression analysis was conducted in order to 
further explore Research Question 2b: Does the interaction term self-efficacy x perceived 
social support at adjusted baseline predict physical functioning 24-months following fetal 
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tissue implantation? This analysis controlled for patients’ length of PD diagnosis and 
level of physical functioning at adjusted baseline. In other words, these control variables 
comprised step one of the regression analysis. As previously described, an interaction 
term was calculated for perceived social support and self-efficacy at adjusted baseline. 
The interaction term was calculated by multiplying the centered values (score – mean) of 
the social support and self-efficacy variables at baseline. The interaction term and the 
centered social support and self-efficacy variables were entered into the analysis as step 
two.  
The regression model, with centered social support, centered self-efficacy, and the 
centered interaction term as predictors, was not statistically significant, R2(5,14) = .44,  p 
= .11, although the model comprised of the control variables, length of PD diagnosis and 
physical functioning at adjusted baseline, was significant (see Table 11). The interaction 
term was not found to be a statistically significant predictor of physical functioning 24-
months post-fetal tissue implantation (β = .32, p = .18). As previously described, the 
control variable, physical functioning at adjusted baseline (β = .43, p < .1) was found to 
be a statistically significant predictor of physical functioning 24-months post-fetal tissue 
implantation; length of PD diagnosis (β = -.07, p = .76) was not statistically significant. 
See Table 11. 
Research question 3. Do self-efficacy and perceived social support at true 
baseline predict perceived treatment at 12-months after the initial surgery? 
A binary logistic regression was conducted in order to answer Research Question 
3. Because the blind was lifted 13-months after the initial surgery, this analyses used true 
baseline values for one of the control variables, physical functioning, as well as for the 
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two predictors of interest, social support and self-efficacy. This analysis controlled for 
patients’ length of PD diagnosis and level of physical functioning at true baseline.  
Table 11 
  
Hierarchical Multiple Regression Analyses Predicting Physical Functioning 24-months 
Post-Fetal Tissue Implantation From Interaction Term Social Support x Self-efficacy 
 
 Physical Functioning 24-months 
Post-Fetal Tissue Implantation 
Predictor R2 ΔR2 Adjusted 
R2 
 β 
Step 1: Control Variables .28* .28* .19*  
PD Duration    -.11 
Baseline Physical Functioning    .51** 
Step 2 .44 .16 .24  
PD Duration    -.07 
Baseline Physical Functioning    .43* 
Centered Social Support    .25 
Centered Self-efficacy    -.15 
Centered Interaction Term 
Social Support x Self-efficacy 
   .32 
Note. * p < .1  ** p < .05. 
The predictors of interest at true baseline, self-efficacy and social support, were 
not found to be significant predictors of perceived treatment group 12-months after the 
initial surgery. Likewise, the control variables, patients’ length of PD diagnosis and level 
of physical functioning at true baseline, were not found to be significant predictors of 
perceived treatment group at 12-months. See Table 12. While it was not statistically 
significant, social support at true baseline was the strongest predictor of perceived 
treatment of those variables included in the model (Wald = .98, p = .33). The addition of 
self-efficacy and social support to the regression model comprised of control variables 
did not significantly improve prediction of perceived treatment group at 12-month 
follow-up (χ2 = 2.55, p = .64). The prediction model, including social support and self-
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efficacy, accounted for 13.5% of variance in perceived treatment (Nagelkerke R2 = .135) 
and the model was found to provide good fit (χ2 = 10.49, p = .23). 
Table 12 
Logistic Regression Analyses Predicting Perceived Treatment 12-months After Initial 
Surgery From Social Support and Self-efficacy at True Baseline 
 
 Perceived Treatment 
Variable B Wald 
Constant .74 .35 
Length of PD Diagnosis -.04 .21 
Physical Functioning at True 
Baseline 
.19 .93 
Self-efficacy at True Baseline -.06 .01 
Social support at True Baseline -.49 .98 
χ2  2.55  
n 24  
Note. * p < .1. 
Summary 
 
Chapter Four presented the results of the statistical analyses conducted to examine 
the research questions of the present study. A description of the preliminary analyses was 
provided and followed by the findings of the primary analyses. Chapter Four included 
each of the following subsections: a) demographic information; b) descriptive statistics of 
QoL measures; c) reliability of variables used to answer research questions; d) 
correlations of QoL variables; e) creation of the composite variable; f) primary results for 
Research Question 1; g) primary results for Research Question 2a; h) primary results for 
Research Question 2b; and i) primary results for Research Question 3.  
Results of the analyses for Research Question 1 revealed strong, linear 
relationships between self-efficacy at adjusted baseline with the physical functioning 
composite at 12-months post-fetal tissue implantation. The analyses did not reveal strong, 
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linear relationships between perceived social support at adjusted baseline with the 
physical functioning composites at 12- or 24-months post-fetal tissue implantation.  
Results of Research Question 2a revealed that self-efficacy at adjusted baseline 
was a significant predictor of physical functioning 12-months post-fetal tissue 
implantation. Specifically, as self-efficacy scores increased, physical functioning scores 
decreased or, in other words, improved. Social support was not found to be a significant 
predictor of physical functioning 12-months post-fetal tissue implantation. Moreover, it 
was observed that as total scores on the social support scale increased, the physical 
functioning composite score also increased or, in other words, worsened (lower scores on 
the physical functioning composite suggested better functioning). The interaction term, 
social support x self-efficacy, was not a significant predictor of physical functioning at 
12-months post-fetal tissue implantation.  
Results of the analyses for Research Question 2b suggested that adjusted baseline 
levels of social support and self-efficacy were not significant predictors of physical 
functioning 24-months post-fetal tissue implantation. Likewise, the interaction term, 
social support x self-efficacy, was not a significant predictor of physical functioning 24-
months post-fetal tissue implantation.  
Finally, results for Research Question 3 revealed that social support and self-
efficacy scores at true baseline were not significant predictors of patients’ perceived 
treatment group 12-months after the initial surgery, or before the blind was lifted at the 
13-month follow-up.  
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Chapter Five will discuss the conclusions and clinical implications of the 
statistical results presented in Chapter Four. Chapter Five will also present the limitations 
of the present study and recommendations for future research.  
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Chapter Five: Discussion 
Overview 
Chapter Five presents a summary of the present study, a discussion of the study 
results, clinical implications of the study findings, limitations of the study, and 
recommendations for future research.  
Summary of the Present Study 
Few studies have comprehensively explored the benefit of fetal tissue 
implantation in PD patients (Lindvall et al., 2004). In particular, researchers have not 
identified the factors that make patients good candidates for this surgical intervention 
with the exception of age, as discussed in Freed et al.’s investigation (2001). Variables 
that likely contribute to positive outcomes following the surgical procedure have not been 
explored. Similarly, few studies have investigated the mechanisms through which 
potential benefits of fetal tissue implantation likely operate (Lindvall et al., 2004; McRae 
et al., 2004). This type of investigation is necessary in order to better understand how and 
why some participants in a double-blind investigation of fetal tissue implantation for PD 
improved following the surgical procedure while others did not (Freed et al., 2001). This 
sort of study informs future surgical interventions with PD patients and assists in 
selecting candidates who might benefit more than others. Furthermore, this information 
assists in determining domains of patient life that may require preliminary intervention or 
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improvement prior to undergoing an invasive surgical procedure such as fetal tissue 
implantation.  
The present study attempted to address this gap in the literature by exploring the 
relationship of self-efficacy and social support with physical functioning in PD patients 
following fetal tissue implantation. In particular, this study examined the relationships 
between self-efficacy, social support, physical functioning, and perceived treatment in a 
sample of PD patients who either received fetal tissue implantation at the start of the 
parent study or a sham surgery followed by actual fetal tissue implantation (Freed et al., 
2001). The goal of the present investigation was to contribute to the literature by 
examining the role of self-efficacy and social support in regard to physical functioning 
and perceived treatment observed in PD patients following fetal tissue implantation.  
 Data for the present study were collected during a QoL life study conducted by 
McRae et al. (2004) that sampled PD patients who participated in a double-blind 
investigation of fetal tissue implantation (Freed et al., 2001). Thirty of the 40 patients 
who participated in Freed et al.’s (2001) parent study agreed to participate in the QoL 
study. Data related to a variety of QoL variables were collected at baseline, four-, eight-, 
12-, 24-, and 36-month follow-up assessments. The present study examined the predictive 
ability of self-efficacy and perceived social support at adjusted baseline on patients’ 
physical functioning at 12- and 24-month assessments following fetal tissue implantation. 
Because patients who originally received the sham surgery were given the opportunity to 
have the actual fetal tissue implantation once the blind was lifted 13-months after their 
initial surgery, the present study examined patient data at 12- and 24-months after the 
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actual fetal tissue implantation (or at 24- and 36-months after the initial surgery for those 
in the sham group). The following research questions were investigated: 
1. Are self-efficacy and perceived social support at adjusted baseline correlated 
with physical functioning 12- and 24-months post-fetal tissue implantation? 
2a. Do self-efficacy and perceived social support at adjusted baseline predict 
physical functioning of PD patients 12-months following fetal tissue implantation? Does 
the interaction term of social support x self-efficacy at adjusted baseline predict physical 
functioning of PD patients 12-months following fetal tissue implantation? 
2b. Do self-efficacy and perceived social support at adjusted baseline predict 
physical functioning 24-months following fetal tissue implantation? Does the interaction 
term of social support x self-efficacy at adjusted baseline predict physical functioning of 
PD patients 24-months following fetal tissue implantation? 
3. Do self-efficacy and perceived social support at true baseline predict perceived 
treatment 12-months after the initial surgery? 
Overall Findings 
The first research question was exploratory in nature and designed to describe the 
relationships between the two variables of interest, perceived social support and self-
efficacy, and physical functioning in the study sample. A composite variable was created 
for physical functioning to account for the various measures used in the QoL study to 
assess participants’ overall level of physical functioning (McRae et al., 2004). As 
anticipated, the results revealed strong, linear relationships between self-efficacy at 
adjusted baseline with the physical functioning composite variable at 12-months post-
fetal tissue implantation. While there were some variable relationships that did not 
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demonstrate strong correlations, such as social support with physical functioning at 12- or 
24-months post-fetal tissue implantation, the theoretical and empirical literature indicates 
that the variables of interest, social support and self-efficacy, do in fact influence physical 
functioning (Backer, 2000; Brod et al., 1998; Chenoweth et al., 2008; Taylor, 2003). For 
this reason, along with the experimental nature of the study, the decision was made to 
proceed with the regression analyses proposed in research questions two and three. 
The second set of research questions were designed to examine the predictive 
ability of social support and self-efficacy in regard to physical functioning of study 
participants at 12- and 24-months after receiving fetal tissue implantation. As has been 
discussed, the analyses examined physical functioning 12- and 24-months after the actual 
fetal tissue implantation, not from the time of the initial surgery. Therefore, data for the 
participants who initially received the sham surgery were obtained from follow-up 
assessments at 12- and 24-months after they received the actual fetal tissue implantation, 
or at 24- and 36-months following the initial surgery. Likewise, for those who first 
received the sham surgery, scores of social support and self-efficacy at 12-months from 
the initial surgery were used as the “adjusted baseline” scores, rather than the true 
baseline measured at participants’ entry into the study. The reason for this was to 
investigate relationships over the period from pre-implantation to 12- and 24-months 
post-fetal tissue implantation.  
The results for Research Question 2a revealed that self-efficacy at adjusted 
baseline was a significant predictor of physical functioning at 12-months post-fetal tissue 
implantation. As anticipated, when self-efficacy scores increased, physical functioning 
scores at 12-month follow-up decreased or improved. Social support was not found to be 
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a significant predictor of physical functioning 12-months following fetal tissue 
implantation. Moreover, the direction of the relationship observed in this study between 
social support and physical functioning was not anticipated based on the literature. 
Specifically, as total scores on the perceived social support scale increased, the physical 
functioning composite score at 12-month follow-up also increased or, in other words, 
worsened since lower scores on the physical functioning composite suggested better 
functioning. This result was not expected based on the literature, rather it was anticipated 
that as baseline levels of perceived social support increased, physical functioning at 12-
month follow-up would decrease or improve. This unexpected finding is likely explained 
by the small sample size used in the present study. A larger participant sample may 
demonstrate the pattern of variable relationships anticipated from the literature and reveal 
that higher levels of perceived social support predict better physical functioning in 
patients following a surgical intervention such as fetal tissue implantation (Backer, 2000; 
Taylor, 2003). An interaction term was created to examine the collective ability of social 
support and self-efficacy to predict physical functioning 12-months post-fetal tissue 
implantation. The interaction term, social support by self-efficacy, was not found to be a 
significant predictor of physical functioning at 12-months post-fetal tissue implantation. 
Based on a review of the theoretical literature describing the interrelationship between 
these two constructs, this result was not expected (Chenoweth et al., 2008; Kaşikçi & 
Alberto, 2007).  
Results of the analyses for research question 2b indicated that adjusted baseline 
levels of social support and self-efficacy were not significant predictors of physical 
functioning at 24-months post-fetal tissue implantation. Likewise, the interaction term, 
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social support by self-efficacy, was not found to be a significant predictor of physical 
functioning at 24-months post-fetal tissue implantation. Therefore, it seems that within 
this PD sample, the ability of self-efficacy to predict physical functioning following fetal 
tissue implantation was observed at the 12-month follow-up but was not maintained by 
the 24-month follow-up.  
Finally, the third research question was designed to determine if true baseline 
scores of social support and self-efficacy were predictive of patients’ perceived treatment 
before the blind was lifted 13-months after the initial surgery. The results revealed that 
social support and self-efficacy scores were not significant predictors of perceived 
treatment group at 12-months, an unanticipated result based on the literature (Crow et al., 
1999; Howard, 2008; Kaptchuk et al., 2008; Miller et al., 2009).  
Clinical Implications 
The present study demonstrated the important role of self-efficacy as a predictor 
of physical functioning 12-months after fetal tissue implantation. Specifically, higher 
levels of self-efficacy were predictive of better physical functioning. Surprisingly, the 
relationship observed between social support and physical functioning was not in the 
anticipated direction. Theoretical literature suggested that higher levels of perceived 
social support would be predictive of better physical functioning, not worse physical 
functioning which was observed in the present study (Backer, 2000; Taylor, 2003). Other 
studies examining QoL variables in this participant sample have suggested that social 
support continues to be an important predictor of physical functioning more than 10 years 
after fetal tissue implantation (Fazio, 2008).  
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One possible explanation for this finding may be that a third variable not included 
in the analyses, specifically negative affectivity, mediated the relationship between 
perceived social support and physical functioning. The prevalence of depression in the 
PD population has been estimated between 40-50% and is associated with many poor 
outcome variables, such as quality of life, progression of physical symptoms, and ability 
to care for oneself (Ravina et al., 2007; Schrag, 2006). In fact, depression is considered to 
be the most common neuropsychiatric problem in patients with PD (Papapetropoulos, 
Ellul, Argyrio, Chroni, & Lekka, 2006). Some literature argues for a more organic cause, 
citing examples of depression that occurred before the onset of motor symptoms 
(Papapetropoulos et al., 2006). While other literature contends that the psychosocial and 
environmental stressors that are associated with a chronic disease, such as PD, influence 
its development (Papapetropoulos et al., 2006). Regardless of its etiology, depression has 
adverse effects on quality of life. The negative or maladaptive cognitive styles associated 
with depression may influence how PD patients perceive their social support and 
subsequently influence their physical functioning. 
Therefore, despite the direction of the relationship observed in the present study 
between social support and physical functioning, the significant findings of the present 
study, in conjunction with other follow-up studies with this participant sample, argue that 
medical research should examine social support and self-efficacy as predictors of 
physical functioning following surgical interventions such as fetal tissue implantation. 
Benefits of social support and self-efficacy are extensively recognized and studied in 
psychological research, but these variables are not examined as consistently in medical 
research. If variables such as perceived social support and self-efficacy are maximized, 
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patients may demonstrate a greater responsiveness to these types of medical 
interventions.  
As previously discussed, psychological interventions have been developed to 
increase levels of self-efficacy in the chronic disease population (Ritter, Lee, & Lorig, 
2011; Lorig et al., 2001). Results from these studies demonstrate multiple beneficial 
health outcomes due to increased self-management self-efficacy, such as decreased 
disability, fewer medical visits, and less fatigue, and they appear to be maintained over 
time (Ritter, Lee, & Lorig, 2011; Lorig et al., 2001). Few studies have examined the role 
of self-efficacy in the management of PD; however, there is some evidence that suggests 
that there are beneficial effects of high levels of self-efficacy on the management of PD 
(Chenoweth et al., 2008; Peteet, 2002, as cited in Chenoweth, et al., 2008; Montgomery 
et al., 1994). Results from the present study are consistent with the findings of the few 
studies that have examined the role of self-efficacy in management of PD. Although self-
efficacy was found to predict physical functioning only at 12-months after fetal tissue 
implantation, these findings have clinical implications. The results suggest that 
psychological interventions intended to increase PD patients’ self-efficacy, such as those 
developed by Lorig et al. (2001), may enhance patient responsiveness to surgery and 
other medical interventions and may improve their overall disease management.  
Limitations of the Present Study 
The present study includes several limitations. The sample size of the present 
study (N= 30) was small, as it was identical to the original sample used in the QoL study 
(McRae et al., 2004). The participant sample for the QoL study was drawn from the 
parent study. Because of the unique nature of the surgical procedures used in the study 
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design, the parent study only recruited 40 participants (Freed et al., 2001). This small 
sample size limits the generalizability of the study’s findings and clinical implications. 
Particularly, findings from the present study cannot be generalized to the PD population 
at large due to the unique design of this study and the unusual participant sample who 
agreed to receive experimental brain surgery for the treatment of their disease. The 
individuals who volunteered to participate in the parent study, which included the use of 
a sham surgical procedure, are not likely representative of the PD population at large. 
Therefore, conclusions from the present study cannot be generalized outside of the 
individuals who participated in the study. Furthermore, due to the small sample size the 
decision was made to set the alpha level at .10 for all statistical analyses. This alpha level 
increases the chance of Type I error, or incorrectly rejecting the null hypothesis, and is 
another limitation of the present study. Furthermore, the small sample size of this study 
decreased the overall power of the statistical analyses and thus increased the chance of 
Type II error, or failing to reject the null hypothesis.  
Research questions for the present study were assembled in consideration of new 
developments in surgical procedures for PD, such as deep brain stimulation (DBS). 
However, conclusions from the present study are limited due to the unique study design 
and cannot be generalized to PD patients who are treated with other surgical procedures, 
such as DBS. Nevertheless, examining baseline levels of social support and self-efficacy 
as a routine part of pre-surgical evaluations for PD patients may be an important area of 
future research. A discussion of topics for future research will be provided in the 




Recommendations for Future Research 
In consideration of the study’s findings and clinical implications, several areas for 
future research have been identified. First, it is recommended that future studies use 
larger sample sizes in order to expand the external validity or generalizability of their 
conclusions. However, it is unlikely that the unique nature and conditions of the present 
study would be replicated in future studies.  
Second, it is recommended that future studies examining the effects of surgical 
procedures for PD patients continue to investigate the QoL variables that were examined 
in the present study. Specifically, the present study has indicated that baseline levels of 
self-efficacy have an impact on physical functioning 12-months after surgery; therefore, 
future studies might consider examining the influence of these QoL variables on physical 
functioning in patients who are treated with new surgical interventions for PD. For 
example, a European research consortium named TRANSEURO (2013) is currently 
conducting a study examining the efficacy of fetal cell-based treatments in PD patients. 
The results of the present study argue that the researchers with TRANSEURO (2013) 
examine the role of QoL variables, such as social support and self-efficacy, in their study 
in order to maximize patient responsiveness to the fetal tissue implantation. The 
unexpected results of the perceived social support predictor in the present study appear to 
indicate the need for a more thorough investigation of the domain of emotional 
functioning and its relationship to social functioning in the prediction of physical 
functioning in the PD population.  
Finally, future research studies might also consider developing and examining the 
effectiveness of interventions that improve patients’ perceived social support and self-
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efficacy before undergoing invasive surgical procedures. These interventions have the 
potential to increase patients’ responsiveness to surgery and therefore improve their 
overall physical functioning and quality of life. While the findings of the present study 
did not suggest that the interaction between social support and self-efficacy was a 
significant predictor of physical functioning, the literature on these two constructs 
contend that they may be interrelated (Chenoweth et al., 2008; Cutrona & Russell, 1987; 
Kaşikçi & Alberto, 2007). This interrelationship suggests that the two constructs should 
be examined collaboratively, especially among chronic disease populations like PD. 
Therefore it is recommended that future research continue to collectively examine social 
support and self-efficacy as potential predictors of physical functioning and overall 
disease management.  
Conclusions 
The present study examined the predictive ability of baseline levels of perceived 
social support and self-efficacy on physical functioning and perceived treatment in a 
sample of PD patients who received fetal tissue implantation. The study uniquely 
contributed to the literature, as it was the first to examine the role of self-efficacy and 
social support within the participant sample as well as the interaction between self-
efficacy and social support on physical functioning and perceived treatment.  
The study concluded that self-efficacy was a significant predictor of physical 
functioning at 12-months post-fetal tissue implantation. Social support was not found to 
be a significant predictor of physical functioning. These QoL variables were not found to 
be significant predictors of physical functioning at 24-months post-fetal tissue 
implantation or of perceived treatment group 12-months after the initial surgery. Future 
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research studies might consider examining the longitudinal role of social support and 
self-efficacy on patient responsiveness to and benefit from surgical interventions as well 
as the efficacy of clinical interventions designed to enhance these QoL variables in PD 
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Unified Parkinson’s Disease Rating Scale (UPDRS) – Patient Version 
 
How well can you perform these daily activities AT YOUR BEST?  
(check one for each row) 
 
Need   Unable 
Normal  Adequate  Limited  Help   To Do 
Walking  ______  ______  ______  ______  ______ 
Dressing  ______  ______  ______  ______  ______ 
Cutting food  ______  ______  ______  ______  ______ 
Hygiene  ______  ______  ______  ______  ______ 
Getting up  ______  ______  ______  ______  ______ 
from chair   
Turning in bed ______  ______  ______  ______  ______ 
Writing   ______  ______  ______  ______  ______ 
Talking  ______  ______  ______  ______  ______ 
 
How well can you perform these daily activities AT YOUR WORST? 
(check one for each row) 
Need   Unable 
Normal  Adequate  Limited  Help   To Do 
Walking  ______  ______  ______  ______  ______ 
Dressing  ______  ______  ______  ______  ______ 
Cutting food  ______  ______  ______  ______  ______ 
Hygiene  ______  ______  ______  ______  ______ 
Getting up  ______  ______  ______  ______  ______ 
from chair   
Turning in bed ______  ______  ______  ______  ______ 
Writing   ______  ______  ______  ______  ______ 





Severity of Symptoms 
 
Please rate the severity of each of the following problems AT YOUR BEST. 
(check one for each row) 
 
Very 
   Normal  Mild   Moderate  Severe  Severe 
Tremor    ______  ______  ______  ______  ______ 
Swallowing     ______  ______  ______  ______  ______ 
Salivation     ______  ______  ______  ______  ______ 
Freezing when   ______  ______  ______  ______  ______ 
walking   
Falling     ______  ______  ______  ______  ______ 
 
 
Please rate the severity of each of the following problems AT YOUR WORST. 
(check one for each row) 
 
Very 
Normal  Mild   Moderate  Severe  Severe 
Tremor    ______  ______  ______  ______  ______ 
Swallowing     ______  ______  ______  ______  ______ 
Salivation     ______  ______  ______  ______  ______ 
Freezing when   ______  ______  ______  ______  ______ 
walking   






Hoehn and Yahr Stage of Parkinson’s disease Scale 
 
Using the scale below, please indicated the number that best describes the present stage 
of your Parkinson’s disease: ____________ 
 
0 = No signs of disease. 
 
1 = Evidence of disease on one side of the body (unilateral disease). 
 
2 = Evidence of disease on both sides of the body (bilateral disease), without impairment 
of balance. 
 
3 = Mild to moderate bilateral disease; some postural instability; physically independent. 
 
4 = Severe disability; still able to walk or stand unassisted.  
 






Free or Restricted Scale 
 
Overall, how free or restricted do you feel in doing what you want to do? 
(check or circle the appropriate number) 
 
1  2  3  4  5  6  7 
I still do everything    I can no longer do the  





Schwab and England Activities of Daily Living Scale 
 
On the scale below, check the one response that best describes you present activity level. 
 
_______ 100%  I feel completely independent. I am able to do all chores  
without slowness, difficulty or impairment. I feel 
essentially normal. I am unaware of any difficulty.  
 
_______ 90%  I feel completely independent. I am able to do all chores,  
but I have some degree of slowness, difficulty or 
impairment. It might take twice as long. I am beginning to 
be aware of my difficulty. 
 
_______ 80%  I feel completely independent in most tasks. However, it  
takes me twice as long. I am conscious of difficulty and 
slowness. 
 
_______ 70%  I do not feel that I am completely independent. I have  
difficulty with some chores. It takes me three to four times 
as long to complete some tasks. I must spend a large 
portion of the day performing tasks. 
 
_______ 60%  I feel as though I am somewhat dependent. I can do most  
chores, but I do them exceedingly slowly and with much 
effort. I sometimes make errors some tasks are impossible.  
 
_______ 50%  I feel pretty dependent. I help with about half of my daily  
tasks and I complete these tasks at a very slow pace. I have 
difficulty with everything.  
 
_______ 40%  I feel very dependent. I am able to assist with all tasks, but  
can do few things alone. 
 
_______ 30%  Now and then, with a great deal of effort I can begin or  
complete a few chores alone; however, I need a lot of help.  
 
_______ 20%  I can do nothing alone. I can be a slight help with some  
tasks. I am a severe invalid.  
 
_______ 10%  I am totally dependent and helpless. I am a complete  








How certain are you that you can: 
 
1. Do something to help yourself feel better if you are feeling blue? 
 
1  2  3  4  5  6  7 
 Very uncertain      Very certain 
 
2. Deal with frustration that is often part of having Parkinson’s disease? 
 
1  2  3  4  5  6  7 
Very uncertain      Very certain 
 
3. Manage your situation so that you can continue to do the things you enjoy 
doing? 
 
1  2  3  4  5  6  7 
 Very uncertain      Very certain 
 
4. Make some positive changes in your life? 
 
1  2  3  4  5  6  7 
 Very uncertain      Very certain 
 
5. Handle the emotional ups and downs of having Parkinson’s? 
 
1  2  3  4  5  6  7 
 Very uncertain      Very certain 
 
6. Give support to others? 
 
1  2  3  4  5  6  7 
Very uncertain      Very certain 
 
7. Receive support from others? 
 
1  2  3  4  5  6  7 






Social Provisions Scale (SPS) 
 
In answering the following questions, think about your current relationships with friends, 
family members, co-workers, community members, and so on. Please indicate to what 
extent each statement describes your current relationships with other people (check one 
answer for each item). 
 
Strongly               Strongly 
Disagree Disagree Agree                Agree 
1. There are people I can depend on  _____   _____  _____   _____ 
to help me if I really need it. 
 
2. I feel that I do not have close  _____   _____   _____  _____ 
personal relationships with  
other people. 
 
3. There is no one I can turn to for  _____   _____  _____   _____ 
guidance in times of stress.  
 
4. There are people who depend  _____   _____   _____   _____ 
on me for help.  
 
5. There are people who enjoy the _____   _____   _____   _____ 
same social activities I do.    
 
6. Other people do not view me as  _____   _____   _____  _____ 
competent. 
 
7. I feel personally responsible for _____   _____   _____  _____  
the well-being of another person. 
 
8. I feel part of a group who share  _____   _____  _____   _____ 
my attitudes and beliefs. 
 
9. I do not thing other people respect  _____   _____   _____   _____ 
my skills and abilities. 
 
10. If something went wrong, no one _____   _____   _____  _____ 




Appendix G, continued 
 
Social Provisions Scale (SPS) 
 
Strongly               Strongly 
Disagree Disagree Agree                Agree 
 
11. I have close relationships that _____   _____   _____  _____ 
provide me with a sense of  
emotional security and well-being. 
 
12. There is someone I could talk to _____   _____   _____  _____ 
about important decisions in my life. 
 
13. I have relationships where my _____   _____   _____  _____  
competence and skill  
are recognized. 
 
14. There is no one who shares my _____   _____   _____  _____ 
interests and concerns. 
 
15. There is no one who really relies  _____   _____   _____   _____ 
on me for their well-being. 
 
16. There is a trustworthy person  _____   _____   _____   _____ 
I could turn to for advice if I were 
having problems. 
 
17. I feel a strong emotional bond  _____   _____   _____   _____ 
with at least one other person. 
 
18. There is no one I can depend on  _____   _____   _____   _____ 
for aid if I really need it. 
 
19. There is no one I feel   _____   _____   _____   _____ 
comfortable talking about  
problems with. 
 
20. There are people who admire my  _____   _____   _____   _____ 
talents and abilities. 
 






Appendix G, continued 
 
Social Provisions Scale (SPS) 
 
 
Strongly               Strongly 
Disagree Disagree Agree                Agree 
 
22. There is no one who likes to do the _____  _____   _____  _____ 
things I do. 
23. There are people I can count on in _____  _____   _____   _____ 
an emergency. 
 







INFORMATION ABOUT YOU 
 
1. Gender: (check one)  ______Male   ______Female 
 
2.  Age: ______ 
  
3. What is your racial/ethnic background? (check one) 
  
 ______ Native American ______ Black  ______White   
______ Hispanic  ______Asian  ______ Other 
 
4. How many years of school have you completed? (circle last year completed) 
 
HIGH SCHOOL     YEARS OF  
     COLLEGE/VOCATIONAL SCHOOL 
9   10   11   12   1 2 3 4 5 6 more than 6 
 
5. What is your current living situation? (check one) 
 
_____Living with a partner or family member 
_____Living with a friend or roommate 
_____Living alone 
_____Living in a residential setting 
 
6. What is your current marital status? (check one) 
 
_____Never been married 
_____Married or living with partner 
_____Separated or divorced 
_____Widowed 
 
7. If you are married to your partner, how long have you been married? _____ 
 





















_____I used to, but no longer do 
 
11. If not currently employed, what is the main reason? (please check one box only) 
 
_____Temporarily laid off 
_____Retired by my own choice 
_____Forced to retire by my employer 
_____Retired on physician’s advice 
_____Homemaker 
_____Poor health 
_____My job was too stressful, or physically demanding 
_____Other reason (specify): ________________________________________ 
 
12. Do you have any other chronic health problems (e.g., diabetes, heart condition, high 
blood pressure)? (check one) 
 
_____Yes If yes, please describe: _________________________________________ 
_____No 
 
 
 
